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 Understanding the immune defense of the mammary gland is important in devising 
and developing measures to control mastitis. Lipopolysaccharide (LPS) is the 
predominant factor causing pathogenesis in Gram-negative bacterial infections.  The 
cluster of differential antigen14 (CD14), which is located on the surface of leukocytes, is 
the receptor for LPS.  The binding of LPS to CD14 results in release of pro-inflammatory 
cytokines that recruit polymorphonuclear neutrophil leukocytes (PMNs), to the site of 
inflammation, allowing them to kill bacteria through the process of phagocytosis.  This 
research was designed to produce and characterize monoclonal antibodies (mAb) against 
recombinant bovine soluble (rbos) CD14, express rbosCD14 in plants and characterize 
the biological activity of plant-derived rbosCD14 in vitro and in vivo. The release of 
inflammatory cytokines and expression of CD14 on bovine PMN and the secretion of IL-
8 by PMN in response to LPS was also invesitigated.  
A panel of ten murine mAb reactive with rbosCD14 were produced and a sandwich 
ELISA was developed using the mAbs and rabbit polyclonal antibodies. The mAbs 
recognized rbosCD14 (40 kDa), solubleCD14 (sCD14) (53 and 58 kDa) in milk and 
blood, and a 47 kDa mCD14 in lysates of macrophages obtained from involuted bovine 
mammary gland secretions by Western blot analysis.  Flow cytometric analysis showed 
that the mAb bound to macrophages isolated from involuted mammary gland secretions.  
The addition of anti-rbosCD14 mAb to monocytes stimulated with LPS reduced TNF-?
production in vitro. The anti-rbosCD14 mAbs generated in this study will be useful in 
studying CD14, an accessory molecule that contributes to host innate recognition of 
bacterial cell wall components in mammary secretion produced during mastitis. 
 This study demonstrates the functional activity of a recombinant animal receptor 
protein made in plants, and the use of a plant-derived protein as a potential animal 
therapeutic for bacterial infections.  A truncated form of sCD14, carrying a histidine 
residue affinity tag was incorporated with potato virus X for transient expression in 
Nicotiana benthamiana. CD14 from crude plant extracts was recognized by Western blot 
analysis.  Biological activities of plant-derived rbosCD14 (prbosCD14) were 
characterized in vitro and in vivo. Biological activity of prbosCD14 demonstrated in 
vitro by LPS-induced apoptosis, an increase of caspase activity and IL-8 production by 
bovine endothelial cells.  In vivo, prbosCD14 enhanced LPS-induced PMN recruitment 
and in bovine mammary quarters challenged with Escherichia coli that resulted in 
decreased bacterial counts and elimination of clinical symptoms. 
 In this disseration, shedding of sCD14 from the surface of PMN in response to 
LPS was negatively correlated with IL-8 release.  Shedding of sCD14 from the surface of 
PMN increased in the absence of serum and at high concentrations of LPS.  The use of 
real time RT-PCR showed that CD14 gene expression was not different between control 
and the LPS stimulated cells.  This demonstrates that shedding of sCD14 comes from 
membrane-boundCD14 (mCD14).  However, in contrast to the shedding of sCD14, IL-8 
secretion by PMN was decreased at high concentrations of LPS in the absence of serum.  
Moreover, sCD14 secretion from PMN stimulated with LPS was increased in parallel 
with the decrease of IL-8 secretion at varying PMN cell densities.  This result suggests 
that the release of CD14 leads to the down-regulation of IL-8 secretion by PMN in 
response to LPS. 
Bovine PMN produced different types of cytokines in response to LPS in this 
disseration.  The secretion of TNF-?, IL-1B, IL-8 and INF-C by PMN increased in a dose-
dependent manner, but IL-12 secretion by PMN was decreased with increasing 
concentrations of LPS.  Co-incubation of LPS with either TNF-? or IL-1B increased 
secretion of IL-8 when compared to LPS alone. 
 These studies contribute to a better understanding of the interrelationship between 
bovine CD14 and LPS during mastitis and provide new insights into events that resolve 
inflammation following bovine PMN activation. 
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1Chapter One: Literature Review 
 
INTRODUCTION
Bovine coliform mastitis is the most costly disease in dairy cows (145).  Despite 
major successes in the reduction in prevalence of intramammary infections, clinical 
mastitis due to Escherichia coli, environmental streptococci, and Staphylococcus aureus 
remains an important problem (47, 79, 218).  E. coli is the most common Gram-negative 
pathogen (193).  About 80% of coliform infection will result in clinical mastitis, and 10% 
will result in acute mastitis with a sudden onset of septic shock.  Clinical mastitis causes 
decreased milk production, increased veterinary costs, and possible death or culling (145).  
Although several strategies such as improved herd sanitation, antibiotic therapy, and 
vaccination have been developed to reduce the occurrence of mastitis, they are not 
effective in preventing or eliminating infections.  
Gram-negative bacteria possess lipopolysaccharides or endotoxins, which form 
part of the outer layer of the cell wall. Once infection has occurred, the E. coli bacteria 
proliferate in great numbers and produce endotoxin. The release of this endotoxin triggers 
a cascade of inflammatory responses resulting in acute swelling of the mammary gland 
and a marked increased in the number of neutrophils in the milk (195). The cluster of 
differential antigen14 (CD14)-mediated response to LPS, is an important pathway 
utilized by the host for activating cells to LPS.  The role of bovine CD14 to LPS has not 
been fully defined, but previous studies have shown that the intramammary co-
administration of sCD14 with an inoculum of E. coli enhanced bacterial clearance and an 
early influx of white blood cells (118, 119).  The purpose of this research is to provide a 
better understanding of the interrelationship between CD14 and LPS by using anti-
2rbosCD14 mAb, and explore the possibility of using a plant-derived CD14 protein as a 
potential animal therapeutic for bacterial infection.    
Polymorphonuclear neutrophil leukocytes (PMN) play a key role in a cow’s 
defense against intramammary infection by E. coli (27).  Effective elimination of the 
pathogen by PMN is important for the resolution of infection and the outcome of E. coli 
mastitis (237).  PMN and macrophages are the functional phagocytic cells of the body.  
Macrophage and epithelial cells initiate the inflammatory response necessary to eliminate 
invading bacteria.  These cells release chemoattractants for rapid recruitment of PMN to 
foci of infection.  Initiation of the inflammatory reaction is caused by the production and 
release of tumor necrosis factor (TNF), interferons (INF), and interleukins (IL).  These 
complex interactions result in accumulation of PMN in the mammary gland.  
Phagocytosis by PMN is the most effective defense against bacterial infection.  However, 
the release of pro-inflammatory cytokine producing by bovine PMN is not.  Studies in 
my thesis suggest that in addition to their phagocytic and bactericidal properties, PMN 
may play a supportive role by producing pro-inflammatory cytokine and CD14 in the 
innate immune response to infection by Gram-negative bacteria. 
 
BACKGROUND 
1. The structure and host response of LPS  
 The rapid and vigorous inflammatory response to toxic bacterial cell wall 
products, such as LPS, is part of the host innate immune response, which provides the 
first line of defense against invading pathogens (188, 217). 
3LPS is a component of the outer leaflet of the outer membrane of Gram-negative 
bacteria such as E. coli. LPS is a highly pro-inflammatory molecule that is shed from the 
bacterial surface during bacterial replication or death.  LPS molecules from these Gram-
negative bacteria are divided into three distinct regions:  a hydrophobic membrane anchor 
designated lipid A, a short chain of sugar residues with multiple phosphoryl substituents, 
referred to as the core oligosaccharide, and a structurally diverse, serospecific polymer 
composed of oligosaccharide repeats, termed the O antigen (Figure 1).    
 Lipid A functions as a membrane anchor for LPS molecules, and is also 
known to be responsible for the variety of biological effects observed in mammals during 
Gram-negative sepsis.  There are 106 lipid A residues and 107 glycerophospholipids in a 
single cell of E. coli.  LPS has become synonymous with “endotoxin ’’, as a reflection of 
these biological properties of lipid A portion of the molecule.  Lipid A-related 
bioactivities include endotoxic shock, generation of fever, and non-specific activation of 
host lymphocytes and macrophages (166).  
O antigens are made up of repeating oligosaccharide units and are attached via 
specific sugars in the outer core to the lipid A membrane anchor.  An enormous number 
of O antigen structures results from variability within the repeat unit in the type, linkage, 
and substitution of its component sugars, which make the vast serological diversity 
observed for E. coli. For instance, more than 170 different O antigens have been 
identified in E. coli (94). 
 
4Figure 1. Generalized structure of the LPS of E. coli. Core sugar residues are designated 
by sugar abbreviation and number to facilitate identification. (*): Depending upon the 
core type, there can be sugar substituents branching out from the main carbohydrate 
backbone at these locations. (**): The linkage point for O antigen to the core can vary. 
The number of O antigen repeats generally numbers between 1 and 40. This is based on 
the review paper (230). 
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5LPS induces a cascade of host responses including the production of pro-
inflammatory cytokines and mediators, and activation of complement and coagulation 
systems.  LPS activates monocytes and macrophages to produce pro-inflammatory 
cytokines such as TNF-?, IL-1 and IL-6, which serve as endogenous mediators of 
inflammation through receptor-mediated interactions with various target cells.   Pro-
inflammatory cytokines and mediators further stimulate the hypothalamic-pituitary-
adrenal axis, and results in metabolic changes of the host such as onset of the acute phase 
response for maintaining homeostasis during Gram-negative bacterial infections (20).   
Although cytokine production is important for the efficient control of growth and 
dissemination of invading pathogens, overproduction of cytokines is harmful for the host.  
High concentrations of TNF results in dramatic pathophysiological reactions such as 
fever, leucopoenia, hypotension, disseminated intravascular coagulation, and multi-organ 
failure observed in septic shock syndrome (178).  In contrast during sepsis, endotoxin 
tolerance may represent a protective mechanism whose primary function is to limit 
inflammatory damage due to excessive activation of monocytes and macrophages by LPS 
and prevent development of septic shock (167, 200).  
 The most common Gram-negative pathogens implicated in bovine mastitis are E. 
coli, Klebsiella pneumoniae, and various species of Enterobacter (60, 61).  LPS is found 
in the outer membrane of these bacteria.  The bovine mammary gland is highly sensitive 
to LPS (31, 136).  Mastitis may be induced by intramammary injection of LPS-derived 
from E. coli 026:B6, 055:B5, or 0111:B4 (98, 136, 156, 219) and LPS is detectable in the 
milk of cows with coliform mastitis (5, 81). Absorption of LPS into the blood during 
6experimentally induced (58) and naturally occurring E. coli mastitis (103) has been 
reported.  
 
II. LPS recognition: LBP, CD14 and Toll like receptor 
The first host protein involved in LPS recognition is LBP (LPS binding protein) 
(182).  LBP, a glycosylated 58-kDa protein, is an acute-phase protein produced in the 
liver that circulates in the bloodstream where it recognizes and forms a high-affinity 
complex with the lipid A moiety of LPS, as either free molecules, fragments or bound to 
the outer membrane of intact bacteria (182, 210, 226).   
LBP belongs to a family of lipid-binding proteins, which include bactericidal 
permeability increasing protein, cholesterol ester transfer protein and phospholipid 
transfer protein.  LBP is normally found in plasma in low (:g/ml) concentrations, but 
increases by up to 30-fold in plasma during the acute-phase response.  The concentration 
of bovine LBP in milk was reported to be about 6 µg/mL (14). 
 The role of LBP appears to be that of aiding LPS to dock at the LPS receptor 
complex by initially binding LPS, and then forming a ternary complex with CD14.  This 
enables LPS to be transferred to the LPS receptor complex composed of Toll like 
receptor (TLR) 4.  Transmembrane signals are generated to affect cellular functions and 
myeloid differentiation protein (MD)-2 (82, 211) (Figure 2).  LBP alone does not 
stimulate macrophages, or initiate signal transduction pathways in macrophages and 
PMN  (83).    
 CD14 is found in two forms.  The first is solubleCD14 (sCD14), which occurs in 
plasma where it helps to convey LPS signaling in cells lacking membrane-bound CD14 
7(mCD14) e,g, endothelial and epithelial cells (Figure 2).  The second and more extensively 
studied form of CD14 is mCD14, attached to the surface of myeloid cells via glycosyl-
phosphatidyinositol tail (GPI) (91), enabling CD14 to be membrane proximal despite 
lacking a transmembrane domain.  CD14 is also required for the recognition of other 
bacterial products including peptidoglycan, lipoteichoic acid (LTA), and 
lipoarabinomannan (80, 162, 177). 
TLRs have been identified as a major class of receptors recognizing conserved 
bacterial structures called pathogenesis associated molecular patterns.  The main bacterial 
ligands for TLR2 are peptidoglycan and LTA of Gram-positive bacteria. TLR4 recognizes 
LPS of Gram-negative bacteria and LTA.  Each TLR5 and TLR9 recognizes bacterial 
flagellin and bacterial CpG DNA, respectively (234).  
 TLRs support CD14-dependent LPS signaling.  The binding of LPS to mCD14 is 
facilitated by LBP.  mCD14-LPS-LBP complex is recognized by TLR4 (Figure 2).  sCD4 
can efficiently present LPS to TLR4 or peptidoglycan to TLR2 on endothelial and 
epithelial cells that do not express mCD14.  Transmembrane signaling is mediated by TLR, 
where cascades of activation are set in motion, leading to the activation of nuclear factor-
QB (NFQB), activated protein-1, mitogen activated protein kinase (MAPK), and p38.  This 
signaling results in cellular activation and production of pro-inflammatory cytokines (TNF-
?, IL-1, IL-6, IL-12), oxygen radicals, nitric oxide, tissue factors, as well as anti-
inflammatory cytokines like IL-10 and transforming growth factor (TGF).  Biological 
effects induced by LPS are primarily mediated by the cytokines TNF-? and IL-6 produced 
by mononuclear phagocytes and known to be involved in septic shock (22, 114), and by IL-
8, which is a chemoattractant for PMN and granulocyte-activating cytokines (148).  
8Monocytes presented with LPS have a markedly reduced capacity to produce pro-
inflammatory cytokines (especially TNF-?) in response to a second LPS stimulation (96).  
Reduced TNF-? production in septic shock patients was clearly associated with reduced 
numbers of monocytes and decreased expression of CD14. 
Several studies hypothesized that additional transmembrane receptors must act in 
concert with LPS-CD14 complex to initiate the signaling process leading to LPS-induced 
cellular activation.  CD14-blocking monoclonal antibodies could only partially inhibit 
LPS-binding, suggesting the existence of alternative receptors (21, 128, 214, 216).  
Different signaling molecules must be recruited to the site of ligation, which is combined 
with CD14 by LPS.  LPS is released into the lipid bilayer where it interacts with a 
complex of receptors, which include Hsp 70, Hsp 90, CXCR4, GDF5 and TLR4 (214). 
 
9Figure 2. Binding of the LPS-binding protein/LPS complex to mCD14 on monocytes and 
macrphages causes release of pro-inflammatory cytokines and binding of the sCD14/LPS 
complex to Toll receptors on endothelial and epithelial cells causes release of 
chemoattracts. 
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III. Biological function of CD14 
 Human monocytes express high levels of CD14 (~105 receptor/cell) whereas 
CD14 expression on PMN is much lower (~3 x 103 receptors/cell).  CD14 expression on 
tissue macrophages can vary depending upon their origin.  sCD14 occurs in normal 
human plasma at concentrations of 12 µg/mL (111) and in uninfected quarters in cows at 
concentration of 1-6 µg/mL (14, 16, 117).  The cellular source of sCD14 in human milk 
was shown to be mammary epithelial cells, which secrete in culture a slightly smaller 
form of sCD14 than the sCD14 released by monocytes (111). 
CD14 lacks transmembrane and intracellular domains and thus cannot by itself 
initiate signal transduction.  Nevertheless, CD14-deficient mice are highly resistant to 
LPS-induced shock.  Monocytes derived from CD14-deficient mice are insensitive to 
LPS as determined by LPS-induced IL-6 production, suggesting essential roles for CD14 
in binding to LPS (90).  Administration of sCD14 has been demonstrated to inhibit LPS-
induced TNF-? production and decrease fatality in LPS-challenged mice (88, 205).  
Moreover, acquisition of LBP by sCD14 has been shown to transport LPS to high-density 
lipoprotein and lead to neutralization of LPS in plasma (228).  Presumably, sCD14 
competes with mCD14 for LPS to prevent activation of CD14-expressing immune cells.  
Moreover, enriched sCD14 in milk has been reported to act as a B-cell mitogen and play 
a role in breast feeding-associated benefits, such as reduced gastrointestinal infections in 
infants (69, 111).  Blockade of CD14 with anti-CD14 mAbs in rabbits infected with E. 
coli pneumonia, did not alter TNF-?, IL-8, and the number of leukocytes in plasma and 
bronchoalveolar lavage fluid.  Although deleterious systemic responses were prevented, 
the dissemination of bacteria was increased by the blockade of CD14 (74).  Pretreatment 
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with anti-CD14 mAbs prevented LPS-induced hypotension and reduced plasma cytokine 
levels in cynomolgus monkeys and inhibited endotoxin-mediated symptoms and 
inflammatory response in human (122). 
Intramammary injection of recombinant bovine sCD14 (rbos) together with low 
concentrations of LPS into lactating dairy cows caused recruitment of PMN when 
compared to either LPS or CD14 (220).  Intramammary injection of a high concentration 
of LPS causes an increase of sCD14 in milk attributed to shedding of mCD14 from 
recruited PMN, and plays a role in modulating the inflammatory response during 
coliform mastitis (154).  rbosCD14 was able to reduce the severity of intrammmary gland 
infection by E. coli in a mouse mastitis model (118) and also reduced the severity of 
infection in dairy cows after intramammary challenge with E. coli (119).  
 
IV. Defense of bovine mammary gland by PMN 
 
1. The characteristic of PMN 
Polymorphonuclear neutrophil leuckocytes (PMN) form the first line of cellular 
defense against invading bacteria.  PMN play a pivotal role in the defense against 
invading pathogens.  The capability of these cells to react to inflammatory stimuli 
depends on chemotatic, phagocytic, and intracellular killing processes.  In addition, the 
number of circulating PMN before infection has been demonstrated to be crucial to 
determine the outcome of diseases such as E. coli mastitis (92). 
The most prominent characteristic of the PMN is their multilobulated nucleus, 
which allows the PMN to line up its nuclear lobes in a line, permitting rapid migration 
between endothelial cells.  Bovine PMN contain azurophilic and specific granules in 
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addition to a third novel granule that is larger, denser, and more numerous than the other 
two granules.  This third class of granules contains a group of highly cationic proteins 
and is a store of oxygen-independent bactericidal compounds (19). 
 In the human bone marrow, PMN require 10 to 14 days to mature (10).  After 
maturation, they may be stored for a few additional days.  The mature PMN leave the 
hematopoietic compartment of the bone marrow and enter the vascular sinus by traveling 
in migration channels through the endothelial cell layer.  The PMN circulate in the blood 
stream briefly (half-life of 8.9 hours) (32) and leave the blood stream by diapedesis 
between endothelial cells.  Then, PMN enter the tissue where they function as phagocytes 
for 1-2 days.  Longevity of human PMN has been shown to be positively influenced by 
bacterial products such as LPS (116).  During inflammatory processes such as E. coli 
mastitis and LPS-induced mastitis, the depletion of the circulating PMN pool (54) causes 
change in the proportion of the bone marrow progenitors. 
 
2. PMN migration from blood to the mammary gland      
 PMN are the first cells recruited into the milk following bacteria entry into 
the gland and represent the predominant cell type.  PMN have several receptors on their 
cell membranes (Figure 3), which serve in the process of directed migration from the 
blood into the milk compartment, called diapedesis.  Rolling attachment of PMN to the 
endothelium is the first step in the recruitment process and is accomplished by interaction 
between L-selectin on PMN and its ligand on the endothelial cells (106).  Next, the B2-
intergrins (CD11a, CD11b, CD11c, and CD18) are accountable for a strong and sustained 
attachment, followed by transendothelial PMN migration into the extracellular matrix and 
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through the mammary gland epithelium.  The respective role of the two subunits, namely 
CD11b and CD18 in the migration process has been studied using an in vitro diapedesis 
model (194).   
 
Figure 3.  Recognition of bacteria through immunological recognition (CR3, CR1 and 
FC) and non-immunological recognition mechanisms (lectin, carbohydrate and 
hydrophobic interaction) on the surface of PMN. 
 
Following diapedesis through the blood-milk barrier, functionality of milk PMN 
has been shown to be decreased (140).  In vitro, diapedesis reduced PMN phagocytosis 
and oxidative burst activity following migration across a mammary epithelial cell layer 
(196).  Migration across the endothelium is almost completely dependent on CD18, and 
to a lesser extent, on CD11b, whereas the diapedisis across the mammary gland epithelial 
barrier is more dependent on CD11b.  Migration across the collage of the extracellular 
FC 
lectin hydrophobicity 
Phagocyte 
CR3 
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matrix was partly dependent on CD18, but completely independent of CD11b (197).  At 
the same time that Mac-1 expression increases, L-selectin is proteolytically shed from the 
PMN surface (106). CD18 molecule allows PMN to bind tightly to activated endothelium 
via another endothelial molecule, ICAM (intercellular adhesion molecular)-1.  This 
second adhesive interaction allows PMN to migrate along the endothelial surface and into 
tissue along a concentration gradient of chemoattractants, the most important being 
complement components C5a and C3a, LPS, IL-1, IL-2 and IL-8 (40, 43, 77, 209).   
3. Phagocytosis and intracellular killing  
At the site of infection, activated PMN recognize bacteria through immunological 
receptors (CR1, CR3, FcR) or non-immunological receptors (lectin, carbohydrate, and 
hydrophobicity) (Figure 3). Immunological recognition is accomplished by specific 
antibodies (IgM or IgG2) on bovine PMN. They recognize bacterium through Fab regions 
and bind to PMN via Fc-receptors (FcR) on the plasma membrane.  The C3b component 
of complement also opsonizes bacteria and binds to CR1 receptor on PMN.     
Next, PMN phagocytose and kill bacteria through their oxygen-dependent and oxygen-
independent bactericidal mechanisms (27).  Inflammatory cytokines such as IL-1, TNF- ?
or INF-C can enhance PMN phagocytosis and/or their bactericidal activity.   
Milk PMN are less functional phagocytic and bactericidal than the homologous 
circulating cells.  Milk fat globules and casein are ingested and cause a loss of 
cytoplasmic granules in PMN.  These are associated with a reduction in bactericidal 
activities and leukocyte rounding that eliminates the pseudopods needed for phagocytic 
capabilities.  In addition to their phagocytic capabilities, PMN are a source of anti-
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microbial proteins, such as lactoferrin, bactenecins, and defensins.  After ingestion and 
release of their chemicals, most of the PMN perish.  Next, macrophages migrate through 
the pores of the capillaries.  Damage to tissue is limited by induction of programmed cell 
death (apoptosis) of PMN, and their bactericidal chemicals are walled off within dying 
PMN that are then ingested by macrophages to minimize further damage to tissue (155).   
PMN recruitment depends on intensity and rapidity according to the pathogens 
and to the cow.  E. coli and S. aureus are the main pathogens accountable for mastitis.  E. 
coli infusion into a healthy gland causes clinical mastitis with severe clinical signs and a 
loss of milk production.  In a few hours, large amounts of the pro-inflammatory cytokines 
such as IL-1 and IL-8 are detected in milk.  PMN recruitment increases rapidly between 3 
and 12 h post-challenge following intrammamary injection of LPS and E. coli, and then 
returns to normal levels (15, 16, 171, 172, 191, 193).  Experimental subclinical S. aureus 
mastitis induces a moderate and a delayed PMN recruitment between 24 and 48 h post-
infection of the challenged glands. 
 
V. The role of cytokines in the mammary gland 
 Experimental coliform mastitis induced by intramammary gland infusion of 
LPS or E. coli has been used for studying the role of PMN in the outcome of 
intramammary infection, and the subsequent development of inflammation.  After 
intramammary infusion of LPS, cytokines such as TNF-?, IL-1 and influx of PMN are 
detectable (14). 
 In vitro studies have shown that mammary epithelial cells may participate in the 
immunoregulation during mastitis via cytokine production.  These cells secrete IL-1 in 
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response to LPS.  IL-1B also appeared to be an important mediator for the release of IL-8 
from mammary epithelial cells (22).  TNF-? and IL-1B were shown to affect tight 
junctions between the epithelial cells, lowering the transepithelial resistance (176) and 
allowing exchange of inflammation metabolites and cells between the two blood-milk 
barrier compartments.  Another action of IL-1 and TNF-? is to activate fibroblasts of the 
mammary gland, with subsequent IL-8 secretion (114).  TNF-? up-regulates PMN 
phagocytosis, adherence, chemotaxis, and release of reactive oxygen species (199).    
IL-8 is a PMN-specific chemoattractant and is produced in the response to 
inflammatory stimuli by a variety of cells (9).  IL-8 induces PMN chemotaxis, respiratory 
burst, degranulation, and increased adherence to endothelial cells (35).  IL-8 stimulated 
the transmigration of PMN through the endo-epithelial barrier in a dose-dependent 
manner suggesting that the production of IL-8 by mammary endothelial cells at the site of 
inflammation plays an important role in the recruitment of PMN into the infected gland 
(120). 
In addition to the role in the pathogenesis of mastitis, cytokines initiate an 
increase in temperature and induction of metabolic changes, and prime or activate PMN.  
Cytokines can change the rate of bone marrow production and release of PMN.  
Cytokines also enhance PMN migration to the infection site, and increase PMN 
phagocytosis and respiratory burst (203).   
 Cytokines mostly have a pleiotropic effect and an autocrine and a paracrine 
function.  Therefore, undesirable side effects are an important obstacle for application of 
cytokines in the field.  Administration of some bovine cytokines in vivo resulted in a 
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positive effect on immunity (44, 147, 169).  Pretreatment of cows with INF-C would exert 
a protective effect against a subsequent experimental infection (200).  
 
VI. Transgenic plants 
In the past several years, recombinant nucleocapsid proteins have been expressed 
in E. coli, in a baculo and vaccinia virus expression system in silkworms and in 
mammalian cells (181).  Recombinant nucelocapsid proteins expressed in insect cells, 
bacteria or as chimaeric HBV core particles, can evoke protective immunity in an animal 
model (231). 
 Recent studies have shown that proteins expressed in plants are effective tools for 
production of antigens.  Bacterial toxins and various viral proteins have been successfully 
expressed in plants.  These proteins were able to elicit specific humoral and mucosal 
immune responses when administered intraperitoneally and protected animals against the 
corresponding bacterial or viral infections (133, 232).  The expression of immunogenic 
viral proteins has been successfully performed in plants and is immunogenic.  Plant 
expression systems have the following advantages over other expression systems.  First, 
the post-translation protein modification takes place in eukaryotic cells.  Second, there is 
no risk of contamination with mammalian viruses or other pathogens, and the production 
of the antigens based on expression of the proteins is inexpensive and therefore of 
economical interest.  An example of the potential usefulness of transgenic plants for 
production and delivery of edible vaccines had been demonstrated for the Norwalk virus 
(133).  Successful expression of the Norwalk virus caspid proteins in transgenic tobacco 
and potato plants and showed good immunogenecity after oral application in mice. 
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OBJECTIVES
The objectives of the studies were: 1) to produce and characterize a panel of anti-
rbosCD14 mAb to be used to reduce the release of inflammatory cytokines from bovine 
macrophages, and to develop an ELISA for quantitating bovine solubleCD14, 2) to 
express recombinant bovineCD14 protein in plants and determine biological activity in 
vitro and in vivo, 3) to investigate the expression and shedding of CD14 molecules and 
it’s effect on the expression of IL-8 in bovine PMN after LPS stimulation, and 4) to 
determine the release of inflammatory cytokines from PMN in response to LPS. 
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Chapter Two: The Production and Characterization of Anti-bovine 
CD14 Monoclonal Antibodies 
 
ABSTRACT
To characterize further the chemical and biological properties of rbosCD14, a 
panel of ten murine monoclonal antibodies (mAb) reactive with recombinant bovine 
CD14 (rbos) were produced.  A sandwich ELISA, using murine mAb and rabbit 
polyclonal antibodies reactive with rbosCD14 was developed.  All the mAbs were 
reactive by ELISA with baculovirus-derived rbosCD14 and they recognized rbosCD14 
(40 kDa) by Western blot analysis.  The mAb also identified by Western blot sCD14 (53 
and 58 kDa) in milk and blood and mCD14 (47 kDa) in a lysate of macrophages obtained 
from involuted bovine mammary gland secretions.  Analysis by ELISA of whey samples 
after intramammary injection of LPS (10 Ng) revealed increased sCD14 levels between 8 
to 48 h after injection.  Flow cytometric analysis showed that the mAb bound to 
macrophages isolated from involuted mammary gland secretions and mouse macrophages 
but not to swine or horse monocytes.  Addition of anti-rbosCD14 mAb to monocytes 
stimulated with LPS reduced in vitro production of TNF-?. The anti-rbosCD14 
antibodies generated in this study will be useful in studying CD14, an accessory molecule 
that contributes to host innate recognition of bacterial cell wall components in mammary 
secretions produced during mastitis.  
 
Introduction 
CD14 was first described as a monocyte/macrophage differentiation antigen  
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that is attached to the cell surface by a GPI anchor (91).  mCD14 is a 55 kDa 
glycoprotein which binds LPS and initiates cell activation.  This receptor is abundant on 
the cell membrane of monocytes and macrophages and is present at a lower density on 
PMN (6).  sCD14 has been detected in bovine milk (110), and in human serum and urine 
(18, 87, 235).  mCD14 is an accessory receptor for LPS that activates monocytes, and is 
capable of binding low concentrations of LPS that are complexed to serum-derived LBP 
(227). 
sCD14 exists in at least two isoforms which range in size from 48-56 kDa (59).  
sCD14 found in human serum has been attributed to the shedding of mCD14 from 
monocytes, macrophages and PMN (59, 100).  Studies with human monocytes and 
monocytic cell lines have shown that mCD14 is released via protease-dependent or 
independent pathways.  Some isoforms originate from shedding of mCD14, while others 
are secreted after synthesis by monocytes and macrophages (25).  sCD14 present in the 
serum/plasma and urine of nephritic patients mediates activation of cells not bearing 
mCD14 including epithelial cells and endothelial cells (7, 75).  Macrophages are the 
predominant cell type in milk from uninfected bovine mammary glands whereas PMN 
predominant in mastitic milk.  Bovine macrophages and PMN in milk express mCD14 on 
their cell surface (154) and are potential sources of sCD14.   
LBP promotes rapid binding of LPS and forms aggregates that bind to mCD14 (227).  
mCD14 is important for conferring sensitive cellular responses to LPS.  LPS induction of 
cytokine release, particularly TNF-? and IL-1, is probably the central most important 
event in initiating the acute-phase response to infection (14).  LPS stimulates the cells by 
ligating specific membrane receptors like CD14 that are important for cytokine release.  
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Anti-CD14 mAb blocks release of TNF-? from macrophages (52, 88) and protects 
primates from endotoxin shock (55, 240). 
Coliform mastitis, which is caused by Gram-negative bacteria, is the most prevalent 
form of clinical mastitis, with infection by E. coli being the most frequent.  
Approximately 80% of all intramammary infections by coliform bacteria will result in 
clinical mastitis, and about 25% of the cows will develop acute clinical symptoms (60, 
61).  Coliforms are present in the cow’s environment and they cannot be eradicated on a 
practical basis.  Conventional herd management practices such as post-milking teat 
dipping, and dry cow antibiotic therapy have been unable to reduce the incidence of new 
intramammary infections by coliforms. Pre-dipping has been shown to decrease 
environment mastitis due to Streptococci and coliforms.  Even in well-managed herds 
coliform mastitis continues to exist as an animal health problem.  In addition, antibiotic 
treatment, extensive fluid supplementation and metabolic support are not effective in 
relieving symptoms associated with clinical coliform mastitis (153).  Anti-bovine CD14 
mAb may provide a means of reducing clinical symptoms during acute coliform mastitis 
by blocking the binding of LPS to mCD14 on monocytes and macrophages, thus down-
regulating release of inflammatory mediators like TNF-? and IL-1.   The objectives of 
this study were to: 1) produce anti-rbosCD14 mAb that could be used to reduce release of 
inflammatory cytokines from bovine macrophages, and 2) develop an ELISA for 
quantitating bovine sCD14.                       
 
MATERIALS AND METHODS
Production of rbosCD14 
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The rbosCD14 was produced in a baculovirus expression system as previously 
described (227).  Briefly, rbosCD14, with a deletion of 14 amino acids at the C-terminal 
end, was generated by insect sf/9 cells infected with recombinant virus containing the 
gene.  The rbosCD14 was purified from culture supernatant using Ni-NTA superflow 
agarose beads (Qiagen, Valencia, CA, USA) and FPLC system (Amersham Pharmacia, 
Uppsala, Sweden) with a typical yield of 4-6 mg/L of culture supernatant.  Functional 
analysis of the rbosCD14 showed that it reduced mortality in mice from endotoxin shock 
and reduced severity of intramammary infection in mice and cows after experimental 
challenge with E. coli (118, 119). 
 
Hybridoma production and mAb purification 
 
Four female BALB/c mice (National Cancer Center, Fredrick, MD, USA) were 
immunized intraperitoneally biweekly with 50 µg of rbosCD14 emulsified in Freund’s 
adjuvant (Sigma, St. Louis, MO, USA).  Six weeks after the second injection and 3 days 
prior to fusion, mice were boosted by intravenous injection of 25 µg of rbosCD14 in 0.5 
mL of 0.01 M phosphate buffered 0.85% saline, pH 7.4 (PBS).  Mice producing high 
serum antibody titers to rbosCD14 were selected by ELISA, and their spleen 
lymphocytes were fused with mouse myeloma SP 2/0 cells (ATCC, Rockville, MD, 
USA). Hybridomas were selected in medium supplemented with hypoxanthine, 
aminopterin, and thymidine (Sigma), and supernatants screened by ELISA (see below).  
Hybridomas secreting rbosCD14 antibodies were cloned by limiting dilution using mouse 
thymus feeder cells. Ascites were produced in female BALB/c mice following 
intraperitoneal injection with 0.5 mL of 2, 6, 14, 20-tetramethypentadecane (Sigma).  
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Purification of monoclonal antibodies 
 Ascties were centrifuged at 500g for 20 min.  The top lipid layer was discared and 
ascites were filtered through glass wool.  Three mL of PBS were added to the ascites.  
Ascties were centrigued for 30 min at 20,000g at 4VC.  Supernatant was filtered through 
0.45 m syringe filter and diluted up to 50 mL with PBS.  Ascties were purified using Hi 
TrapTM proteinG column (Amersham Pharmacia Biotech, Uppsala, Sweden) with FPLC 
(Pharmacia Biotech, NJ, USA).  
 
Polyclonal Antibody Production  
 The immunization protocol is described in detail by Fretterer and Barfield (68).  
Briefly, a New Zealand white female rabbit, 4-5 pounds and specific pathogen-free, was 
purchased from Covance Research Products (Denver, PA, USA).  The ImmuMax SR 
adjuvant system, an immunostimulatory biomolecule, surfactant and oil (Zonagen, Inc., 
The Woodlands, TX, USA), was used to form an emulsion containing 15 µg of 
rbosCD14.  The mixture of gel, rbosCD14 and ImmuMax SR chitosan was brought to pH 
7.0 and emulsified with the surfactant and oil immediately before being injected 
subcutaneously into the scapular arch of the rabbit.  Total volume of the injection was 1.0 
mL and was spread over 3-4 injection sites.  On day 30 post-immunization, this 
procedure was repeated.  Before immunization, rabbits were bled from the central 
auricular artery to obtain baseline control sera.  At 37 days post-immunization, a second 
blood sample was obtained to determine positive antibody response and titer.  
 
Isotyping of mAb 
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A mouse hybridoma isotyping ELISA kit (Biomeda, Foster City, CA, USA) was 
used to isotype the mAb.  Using 96-well microtiter plates, 50 µL of antigen solution was 
added to each well and incubated for 3 h at 37°C.   The plates were washed once with 
PBS, followed by addition of 200 µL of 1% bovine serum albumin (BSA) blocking 
solution to each well and incubated for 1 h at 37°C.  Hybridoma supernatant (100 NL) 
was added to each well and 50 µL of class-and subclass specific anti-mouse antibodies 
was added to the plates and incubated for 30 min at 37°C.  After washing the plates 3 x 
with PBS, 50 µL of rabbit anti-goat IgG conjugated to horseradish peroxidase (Bio-Rad) 
was added to each well and incubated for 30 min at 37°C.  After washing the plate 3 x 
with PBS, 100 µL of 3, 3’, 5, 5’-tetramethylbenzidine (TMB) chromogen/substrate 
solution (Sigma) was added to each well.  The reaction was stopped by adding 50 µL of  
2 N sulfuric acid, yielding a yellow color.   Absorbance was measured using a microtiter 
plate reader (Bio-Tek Instruments, Inc., Winooski, VT, USA) at a wavelength of 450 nm. 
 
Screening for production of anti-rbosCD14 
Flat bottom 96-well microtiter plates (Dynex Technologies Inc., Chantilly, VA, 
USA) were coated with 100 µL of rbosCD14 (10 µg/mL in 0.1 M carbonated-bicarbonate 
buffer pH 9.6) and incubated at 4°C for 16 h.  The plates were washed 3 x with PBS 
containing 0.05% (v/v) Tween 20 (PBS-T).  Each well was blocked with 200 µL of PBS 
containing 1% (w/v) BSA (Sigma) for 1 h at room temperature and washed 3 x with PBS-
T.  Hybridoma supernatants (100 µL) were added and incubated for one hour at room 
temperature, and washed 3 x with PBS-T.  One-hundred µL of HRP-conjugated goat anti-
mouse IgG (H+L; Sigma) diluted 1:2000 in PBS-0.1% BSA was added, and plates 
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incubated for 1 h at room temperature.  The plates were washed 3 x with PBS and then 
100 µL of 0.01% (w/v) TMB in 0.05 M phosphate-citrate buffer, pH 5.0 was added and 
incubated at room temperature for 15 min.  The reaction was stopped with 50 NL of 2 N 
sulfuric acid.  Color change was measured by an automated microtiter plate reader (Bio-
Tek Instruments) at a wavelength of 405 nm.  
 
Preparation of milk whey and blood plasma 
 Milk was obtained from five cows at intervals over a 72 h period after 
intramammary injection of 10 µg of LPS (E. coli 0111:B4, Sigma).  LPS (10 µg) was 
dissolved in 10 mL of 0.85 % saline and sterile filtered through a 0.22 µm cellulose 
acetate filter (Corning Incorporated, Corning, NY, USA).  The right or left front 
mammary quarters were infused with either 10 mL of saline alone or 10 µg of LPS.   
For the preparation of whey, milk samples were centrifuged at 44,000 x g at 4°C 
for 30 min, and the fat layer was removed with a spatula.  The skimmed milk was 
centrifuged again for 30 min as above, and the translucent supernatant collected and 
stored at -70oC in aliquotes.  Blood samples were obtained from the tail vein and 
collected in glass tubes containing K2EDTA (Becton-Dickinson Corp, Franklin Lakes, 
NJ, USA), centrifuged at 1,500 x g for 15 min, and the clear plasma supernatant was 
collected and stored at -70oC in aliquots. 
 
Sandwich ELISA for sCD14 in cow milk after challenge with LPS 
 A sandwich ELISA was used to quantify sCD14 levels in milk whey.  Flat-bottom 
96-well plates were coated with 5 Ng/mL of mouse anti-rbos CD14 mAb M1-54-2  
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diluted in 0.05 M sodium carbonate, pH 9.6 at 4 °C.  This mAb was selected because it 
gave an intensely stained band when used in the Western blot (Table I). The plates were 
washed 4 x with 0.05% Tween 20 diluted in 50 mM Tris buffered saline (TBS), pH 8.0, 
and subsequently blocked with 2% fish skin gelatin (Sigma) for 1 h at room temperature.  
Plates were washed and 100 µL of undiluted whey samples were added to each well.  
Rabbit anti-bovine CD14 polyclonal antibody was diluted 1:2000 in TBS buffer 
containing 0.2% gelatin, and 100 µL was added to each well and subsequently washed as 
above.  One-hundred µL of HRP-conjugated goat anti-rabbit IgG (H+L; Promega) diluted 
in PBS containing 0.2% gelatin (1:5000) was added to each well.  Plates were incubated 
for 1 h at room temperature, washed as above, and 100 µL of TMB substrate solution 
added to each well.  The reaction was stopped by the addition of 50 µL of 2 N H2SO4 and 
the absorbance read at 450 nm on a microplate reader (Bio-Tek Instruments, Inc).   
 
Isolation of macrophages and monocytes and cultivation in vitro 
 Bovine mammary gland macrophages were obtained by daily infusion of 50 mL 
of sterile isotonic saline solution into the involuted mammary quarter of 3 normal adult 
cows for five consecutive days (49).  To avoid infection of the gland, the teat orifice was 
washed with 70% ethanol, and a sterile teat cannula was used to infuse the saline.  
Following gentle massage, the suspension was milked out into a 50 mL plastic conical 
centrifuge tube that contained 25 mL of ice cold PBS.  The samples were kept on ice and 
transported to the laboratory.  The suspension was centrifuged at 250 x g for 15 min at 
4oC.  The cell pellet was suspended in 10 mL of PBS.  Duplicate films were made on 
glass slides and stained with Wright stain using an automatic slide stainer.  Leukocyte 
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differential counts of 200 cells were performed on each slide at a magnification of 1250 
using the battlement procedure (99).  Because large lymphocytes in cows may resemble 
macrophages/monocytes (84) only cells with characteristic amoeboid nucleus and 
vacuolated moderate blue cytoplasm with or without fine azuorphilic granules were 
counted as macrophages (99).  On average, 65% of the cells were macrophages with 98% 
viability as determined with Trypan blue. 
Cross-reactivity of the anti-rbosCD14 mAb was performed using mouse 
macrophages, and porcine and equine monocytes.  For the preparation of mouse 
macrophages, primary cultures of mouse fibroblast/macrophages (MEF/Mac) were 
initiated by explant culture of day-16 to -18 gestation fetal mice after removal of viscera 
(73).  Finely minced fetal mouse tissue was plated in T25 flasks in 2 mL of Dulbecco's 
modified Eagle’s medium with 4.5 g/L glucose (high glucose) supplemented with 10% 
fetal bovine serum, 2 mM glutamine, and 50 U/mL penicillin/streptomycin (10% 
DMEM/H).  After attachment and initial outgrowth (-96 h), 4 mL of additional 10% 
DMEM/H was added to each primary culture flask.  Secondary cultures were produced 
by washing the primary cultures twice with PBS and once with trypsin-EDTA 
solution.  The released cells were resuspended in 10% DMEM/H and replated in T25 
flasks at a 1:3 split ratio.  Secondary MEF/Mac cultures were routinely passaged at a 1:4 
split ratio at 7-day intervals until senescence occurred at approximately passage 12.  A 
culture medium regimen of 3 days on 10% DMEM/H followed by 4 days on 10% 
DMEM/low glucose was maintained over each passage to foster maximum growth of 
the macrophages.  By passage 3-4 approximately 70% of the cells in the cultures were 
macrophages. 
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Monocytes isolated from porcine blood were kindly provided by Dr. Joan 
Lunney, Animal Parasitic Diseases Laboratory, USDA-ARS, Beltsville, MD.  Monocytes 
isolated from equine blood were kindly provided by Dr. Martin Furr, Department of 
Veterinary Medicine, Virginia Tech, Blacksburg, VA, USA. 
 
Immunoblot analysis 
 The rbosCD14 was resuspended in SDS-PAGE sample buffer, heated and 
resolved on a 4-12% Bis-Tris gel (Invitrogen). Separated proteins were 
electrophoretically transferred to Immobilon-P membrane (Millipore, Bedford, MA, 
USA) using the Mini-Protean II transfer chamber (Bio-rad).  The membrane was blocked 
overnight at 4°C in PBS containing 1% BSA, washed 2 x with PBS-T and sequentially 
incubated at room temperature with supernatant of rbosCD14 mAb for 1 h and goat anti-
mouse IgG peroxidase antibody (1: 2000 in PBS-1% BSA) for 30 min.  The membrane 
was washed 5 times with PBS-T, 5 times with distilled water and developed using Sigma 
Fast DAB peroxidase substrate (Sigma).  
 
Flow cytometric analysis  
One-million cells were reacted with anti-rbosCD14 mAb (1:100), and incubated 
at 4°C for 30 min.  The cells were washed 3 x with PBS.  Fluorescein isothiocyanate 
(FITC)-labeled affinity- purified antibody to mouse IgG +IgM (H+L) (KPL, 
Gaithersburg, MD, USA) was added at a 1:100 dilution in PBS to cells reacted with the 
mAb and control cells that were not reacted with mAb.  After 30 min of incubation at 4 
°C, the wells were washed 3 x with PBS and resuspended in 200 µL PBS.  Flow 
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cytometric analysis was performed using a Coulter Epics Profile I-Argon laser flow 
cytometer (Coulter Electronics Inc, Hialeah, FL, USA).  The laser was set at 488 nm 
wavelength, 7.0 to 7.5 A current and 15 mW power; it was aligned by use of 
fluorospheres (Immuno-Check, Epics alignment fluorospheres, Epics Division, Coulter 
Corp, Hialeah, FL, USA).  Gains for forward-angle light scatter were set at 10, and 
logarithmic transformations were used for side (90o) light scatter and for green 
fluorescence.  Locations of the cell populations in dot plots had been determined 
previously on the basis of analyses of pure populations of leukocytes (154).  A bitmap 
(electronically defined observation area) was drawn around the large mononuclear cell 
population that contained both large lymphocytes and macrophages, and fibroblasts for 
the mouse macrophage preparation.  Percentage of cells fluorescing (%F) and the level of 
expression of CD14 molecules (log mean fluorescent channel [LMFC]) were recorded by 
measuring the green fluorescence associated with the gated mononuclear cell population. 
 
Use of anti-rbosCD14 mAb to block in vitro release of TNF-9 from cultured 
monocytes 
Blood from cows was collected from the median caudal vein in 15 mL evacuated 
tubes containing 1.5 mL of acid citrate dextrose (40% trisodium citrate, 14.5% citric acid, 
45.5% dextrose).  For the isolation of monocytes, the blood was centrifuged at 900 x g 
for 30 min at 4VC with the brake disengaged.  The buffy coat layer was removed, and 
transferred into a sterile 40 mL glass vial containing 20 mL Hanks’ balanced salt solution 
(HBSS, Invitrogen Corp., Grand Island, N.Y, USA).  Ficoll-paque (Amersham 
Pharmacia, Biotech, AB, Uppsala, Sweden) (12.5 mL) was layered over the HBSS in a 
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50 mL centrifuge tube.  After centrifuging for 30 min at 450 x g, the band containing the 
mononuclear cell was removed and transferred into a 50 mL centrifuge tube, resuspended 
in 45 mL of HBSS and centrifuged at 180 x g for 10 min at 5VC.  Contaminating red 
blood cells were removed by resuspending the cells in 5 mL HBSS, 10 mL of double 
distilled water was added, gently mixed for 18 seconds and then 10 mL of 2 x minimun 
essential medium Eagle (Sigma) was added to restore isotensitity.  The cell suspension 
was centrifuged 180 x g for 10 min at 5 VC and resuspended in 10 mL HBSS. 
A 1 mL aliquot of the cell suspension containing 105 monocytes was added to 24 
well tissue culture plates and incubated for 1 h at 37VC.  After incubation, the non - 
adherent cells were removed and then 1 mL of medium-RPMI 1630 (Gibco Brl, Life 
Technologies, Grand Island, N.Y, USA) containing penicillin (100 U/mL), streptomycin 
(50 µg/mL) (Sigma, Louis, MO, USA) and 10% heat-inactivated FBS.  Monocytes were 
preincubated with 10 µg of anti-rbosCD14 mAb (M1-54-1) or media for 20 min at 4 VC.  
Next, LPS (0.1, 0.01, and 0.001 ng/mL) was added to the wells and incubated for 24 h at 
37 oC in 5 % CO2. The media from each well was collected and centrifuged at 9,300 x g 
for 30 min.  The supernatant was collected and assayed for TNF-? as previously 
described (154). 
Statistical Methods 
A t-test or analysis of variance with the Tukey post hoc comparison test was used 
to compare the mean responses between a single experimental group and its control or 
among multiple experimental groups, respectively.  All statistical analyses were 
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performed using GraphPad InStat version 3.05 for Windows (GraphPadSoftware Inc., 
San Diego, CA, USA).  A P-value of 0.05 or less was considered significant. 
 
RESULTS 
Production of anti-rbosCD14 mAb 
Following immunization with the rbosCD14, 10 murine hybridomas secreting 
mAb reactive with the immunogen were identified. Table I summarizes the 
immunoglobulins isotypes, ELISA and Western blot reactive assay results.  All 
antibodies were reactive with rbosCD14, but not with BSA, cell culture media, or with 
non-immunized mouse serum that was used as negative controls.  Representative ELISA 
results using the strongly reactive mAb M 1-6-6 are illustrated in Figure 4. 
Intramammary challenge with LPS increases concentration of sCD14 in milk.
To determine whether the mAb could be used to detect and quantify sCD14 in 
whey a sandwich ELISA was used to quantitate sCD14 in milk (Figure 5).  Mammary 
gland quarters receiving saline alone showed no change in sCD14 levels throughout the 
study.  In contrast, significant (P < 0.05) increases in sCD14 were evident within 8 h of 
LPS infusion and this increase persisted for an additional 40 h.  Maximal levels of sCD14 
were observed 24 h after LPS challenge.   
 
Western blotting 
By Western blotting analysis, all mAb reacted with a 40 kDa protein for 
rbosCD14  (Figure 6).  The mAb also recognized 53 kDa and 58 kDa sCD14 in bovine 
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milk and bovine plasma (Figure 6).  Four additional mAb (M 5-29-3, M 4-2-3, M 3-3-8, 
M1-6-6) also strongly recognized a 47 kDa mCD14 protein and a possible accessory 24 
kDa protein from a lysate of mammary macrophages (Figure 7).   However, two 
monoclonal antibodies (M 2-7-2, M 1-54-2) strongly reacted with the 40 kDa 
recombinant protein but not to the macrophage lysate.  Additionally, four monoclonal 
antibodies (M 1-34-9, M 1-52-8, M 3-9-1) showed only one 47 kDa band from the 
macrophage lysate (data not shown).   
 
The binding of mAb to macrophages and cross-reactivity studies 
To study the binding of anti-rbosCD14 mAb to mCD14 on macrophages from 
mammary glands of healthy cows and to perform cross-reactivity studies, flow cytometry 
was performed using mouse anti-rbosCD14 mAb generated in this study.  The reactions 
of the ten anti-rbosCD14 mAbs (diluted 1:1000) with macrophages isolated from 
involuted bovine mammary glands as measured by flow cytometry is shown (Table II).  
After correcting for autofluorescence of the cell preparation (9.9%), the percentage of 
cells recognized by the ten mAbs ranged from 58.0 to 66.9%.  LMFC ranged from 3.0 to 
4.1.  No correction for autofluorescence was applied because with a low percentage of the 
cells fluorescing, the LMFC will be widely scattered along the X axis and will cause 
inflated values for LMFC. mAb M1-6-6 and M3-3-8 showed the highest binding to 
macrophages from involuted mammary secretions and bound to 67% (LMFC 16) of cells 
in a mouse macrophage cell culture.   In contrast, these mAb did not bind to blood 
monocytes isolated from swine and horse blood (Data not shown).   
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TNF-9 release from monocytes incubated with anti-rbosCD14 mAb and exposed to 
LPS 
Inhibitory effect of mouse anti-rbosCD14 mAb (M1-54-1) on the LPS induced 
production of TNF-? by adherent monocytes during 24 h of incubation was dose 
dependent (Figure 8).  The inhibition of TNF-? by anti-rbosCD14 mAb was obtained at 
all concentrations of LPS (1 to 100 ng/mL, P < 0.05).  The greatest inhibition (61%) of 
TNF-? production was achieved when 100 ng/mL of LPS was used to stimulate the 
monocytes.  With 1 and 10 ng of LPS/mL less inhibition (37 and 54 %) was observed.  
The anti-rbosCD14 mAb did not affect the production of TNF-? by unstimulated 
monocytes (data not shown). 
 
DISCUSSION
Several of the mouse anti-rbosCD14 mAb developed in this study showed strong 
reactivity with bovine mammary macrophages by flow cytometry and to sCD14 in milk 
whey when used in an ELISA.  Using the anti-rbosCD14 mAb, we demonstrated that the 
relative molecular mass for mCD14 from the bovine macrophage lysate was 47 kDa 
(Figure 7).  Bovine mCD14 is shorter than human mCD14, which has a molecular mass 
of 50-58 kDa.  Also, the ten murine anti-rbosCD14 mAbs developed in this study show 
different recognition patterns to macrophages by also recognizing a 24 kDa band.  This 
band may be a mCD14 precursor or a truncated mCD14 degradation product.  We also 
demonstrated that sCD14 in bovine milk and blood exists in two forms of 53 and 58 kDa 
(Figure 6).  It was previously shown that mCD14 on monocyte and macrophage exists in 
two soluble forms in normal human plasma (59).  These two sCD14, which are refered to 
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as sCD14 ? (low Mr) and sCD14 B (high Mr), can also be synthesized and released into 
plasma by normal human monocytes.  Different molecular mass forms of sCD14 are 
present in human serum depending on its origin (25, 59, 112).  The lower molecular mass 
forms are derived from the proteolytic cleavage of monocyte mCD14, and, therefore, 
have a truncated C-terminus without the GPI-anchor.  These same cells also produce a 
high molecular mass CD14 receptor lacking the GPI-anchor, which is directly 
exocytosed.  Varying degrees of glycosylation also contribute to the heterogeneity of the 
sCD14 molecule (202). 
 Using the anti-rbosCD14 mAb and ELISA that was developed in this study, we 
were able to demonstrate an increase in sCD14 in milk whey after intramammary 
injection of LPS.  The increase paralleled previously reported increases in sCD14 in milk 
whey in response to LPS using commercially available mAb (14).  In that study, it was 
also shown that increases in milk PMN counts preceded the increase in sCD14.  This 
suggests that PMN may be the source of the sCD14, because it was previously shown that 
PMN express sCD14 on their cell surface (154). 
Effective approaches for the treatment of Gram-negative infections lag behind the 
substantive advances made in understanding host mechanisms involved in response to 
sepsis.  This makes the relationship between the timing of delivery and the efficacy of 
potential therapeutics for septic shock a critical issue.  In the present study, LPS induced 
release of TNF-? by isolated monocytes was reduced by anti-rbosCD14 mAb.  The 
inhibition of TNF-? secretion by anti-rbosCD14 mAb can be explained by reduced 
activation of monocytes during interaction of these stimuli with CD14.  The inhibitory 
effect of anti-rbosCD14 mAb on the secretion of TNF-? by LPS stimulated monocytes 
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can be due to impaired binding of these stimuli to CD14 and/or decreased activation of 
monocytes via CD14.  The region of CD14 that recognizes and binds LPS has been 
determined (204, 220, 239), and most likely Gram-negative bacteria bind via LPS at their 
surface to the same site of CD14.  Intact Gram-negative bacteria can bind to m- and 
sCD14 in the presence of serum (220).  That indicates that LPS incorporated into the 
membrane of Gram-negative bacteria can interact with CD14.  Intact Gram-negative or 
Gram-positive bacteria are more powerful stimuli for cytokine production by monocytes 
than are shed bacterial components (145).  Thus, it is conceivable that exudates from 
macrophage containing phagocytosed bacteria include cytokines that are involved in the 
initial clinical manifestations (145).  It can be anticipated that in vivo, blocking of the 
CD14 receptor will inhibit the inflammatory response to LPS and may be beneficial in 
severe sepsis.  Indeed, anti-CD14 mAb administered after injection of LPS, protected 
rabbits from death and renal and pulmonary injury, and prevented hypotension and 
leukopenia (187).  In cynomolgus monkeys, pretreatment with anti-CD14 mAbs derived 
from the same murine component 28C5 as IC14 prevented LPS induced hypotension and 
reduced plasma cytokine levels (55).  These results support the concept that anti-CD14 
treatment provides a new therapeutic window for the prevention of pathophysiologic 
changes that result from exposure to LPS during septic shock. 
The anti-rbosCD14 mAb developed in the current study may be useful in reducing 
clinical symptoms associated with augmented release of TNF-? by monocytes.  The mAb 
will afford the opportunity to relate various functional characteristics to specific groups 
of cells, which will lead to a better understanding of the interrelationship between CD14 
and LPS.   
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Table I. Immunoglobulin isotype and results from ELISA and Western blot analysis for 
the ten mAb developed in this study. 
 
ELISA Western blot 
Mabs Isotype 
bosCD14 Control bosCD14 Control 
M1-54-1 IgG1,; +++ - +++ - 
M1-34-2 IgG2b,; +++  -  ++ - 
M1-6-6 IgG2b,; +++  -  +++ - 
M3-3-8 IgM,; +++  -  + - 
M1-34-9 IgG2b,; +++  -  ++ - 
M2-7-7 IgG3,; +++  -  +++ - 
M1-54-2 IgG1,; +++  -  +++ - 
M4-2-3 IgM,; +++  -  +++ - 
M5-29-3 IgM,; +++  -  +++ - 
M5-2-8 IgM,; +++  -  + - 
+ = weak reactivity, ++ = moderate reactivity, +++ = strong reactivity 
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Table II.  Reactivity of murine anti-rbosCD14 mAb with macrophages isolated from 
involuted bovine mammary glands (n = 2 cows) as measured by flow cytometry.  
Specific mAb binding was detected by FITC-labeled goat-anti-mouse IgG and IgM.
mAb       Percentage cells fluorescinga,b Log mean fluorescent channelb,c 
M1-54-1  67.4 ± 3.8     3.2 ± 0.7 
 M1-34-2  68.8 ± 2.1     3.0 ± 0.5 
 M1-6-6  74.9 ± 8.7     3.7 ± 0.4 
 M3-3-8  76.3 ± 2.5     4.1 ± 0.5 
 M1-34-9  68.0 ± 4.3     3.2 ± 0.7 
 M2-7-7  71.8 ± 4.4     3.4 ± 0.8 
 M1-54-2  71.6 ± 3.1     3.3 ± 0.6 
 M4-2-3  73.0 ± 8.0     3.4 ± 0.6 
 M5-29-3  72.1 ± 6.5     3.5 ± 0.8 
 M5-2-8  68.9 ± 7.9     3.3 ± 0.8 
 Controld 9.4 ± 3.8     1.9 ± 0.1 
aThe cell preparation averaged 65% macrophages 
bMean ± Standard error of the mean 
cA measure of CD14 receptor density of the cell surface 
dIsolated cell preparation incubated with FITC-labeled goat anti-mouse IgG and IgM 
only. 
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Figure 4. Representative ELISA results for the anti-rbosCD14 mAb developed in this 
study for mAb M1-6-6. Controls include bovine serum albumin (BSA) and glutathione-S-
transferase (anti-GST) a polyclonal antibody purified from goat sera (Pharmacia). 
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Figure 5. A sandwich ELISA was used to quantitify sCD14 in milk obtained from 
mammary quarters of cows that received either saline or LPS (10 Ng). Mean (± SE). N=5. 
Significantly increased compared to saline control at the same time point (* P < 0.05, ** 
P <0.01) 
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Figure 6. Representative Western blotting analysis using mAb M5-29-3 showing 
identification of a 53 and 58 kDa proteins, indicated by arrows, in milk whey (lane 1) in 
blood plasma (lane 2) and a 40 kDa protein in rbosCD14 (lane 3).  Milk whey was 
prepared 8 h after intramammary injection of 100 Ng of LPS. 
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Figure 7.  Representative Western blotting analysis of a macrophage lysate (Lys) using 
anti-rbosCD14 mAb M1-6-6 showing identification of 47 and 24 kDa proteins (arrows). 
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Figure 8. Anti-rbosCD14 mAb (10 µg/mL) inhibits TNF-? response of monocytes after 
stimulation with LPS. Monocytes were preincubated with anti-rbosCD14 for 1 h before 
addition of LPS.  Data are presented as the mean ± standard error of the mean (* = 
P<0.05) 
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Chapter Three: Expression of a Functional Bovine CD14 Receptor in 
Plants 
 
ABSTRACT  
The CD14 antigen is a high affinity receptor for the complex of bacterial LPS and 
LBP in animals.  Binding of the sCD14 to LPS, found in the outer membrane of E. coli 
and other Gram-negative bacteria, enhances host innate immune responses and reduces 
the severity of mastitis.  sCD14 also facilitates clearance and neutralization of LPS, thus, 
protecting against an excessive immune response to LPS and the development of 
endotoxic shock.  In this study, sCD14 protein was expressed in plants with the aim of 
developing a low cost, high yield system to produce a potential animal therapeutic for 
mastitis treatment.  A truncated form of sCD14, carrying a histidine residue affinity tag 
for ease of purification, was incorporated into Potato virus X for transient expression in 
Nicotiana benthamiana. Western blots probed with CD14-specific antibodies 
demonstrated that crude plant extracts and affinity-purified samples contained 
immunoreactive recombinant protein of predicted molecular mass.  Biological activity of 
the plant-derived recombinant sCD14 (prbosCD14) was demonstrated in vitro by LPS-
induced apoptosis and IL-8 production in bovine endothelial cells, and in vivo by 
enhancement of LPS-induced neutrophil recruitment.  Finally, in E. coli infected 
mammary glands subsequently infused with prbosCD14 or saline, lower numbers of 
viable bacteria were recovered from prbosCD14 infused glands, thus, demonstrating 
therapeutic efficacy in the setting of coliform mastitis.  This is the first report of the 
functional activity of a recombinant animal receptor protein made in plants and the use of 
a plant-derived protein as a potential animal therapeutic for bacterial infections.  
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INTRODUCTION 
Macrophages express surface receptors for many bacterial components, including 
LPS.  LPS, also known as endotoxin, is a complex glycolipid in the outer membrane of 
all Gram-negative bacteria. LPS is a highly pro-inflammatory molecule, which, in 
picogram quantities can induce mammalian cells to secrete cytokines, which in turn can 
induce fever, dysregulated coagulation, and systemic vascular collapse (11). 
 CD14 exists in mCD14 as a mediator of LPS signaling and also in sCD14 where 
it binds LPS directly and enhances LPS responses in cells that lack mCD14 (163).  LPS 
interacts with mCD14 on macrophages after formation of a complex with LBP, the latter 
of which functions to transfer LPS monomers to mCD14. mCD14-LPS complexes then 
activate TLR4, a transmembrane receptor involved in the activation of intracellular LPS 
signaling pathway, that, via its cytoplasmic domain, transduces the signal downstream.  
Activation of one such signaling pathway leads to the release and translocation of NF-QB, 
a transcription factor, which up regulates expression of pro-inflammatory cytokines.  
 Mastitis has a significant economic impact.  Discarded milk, increased culling 
and, in some cases, death, further increase the expense.  Estimates of total cost have 
ranged from $200 to $300 per cow per year.  The total cost to the dairy industry in the 
United States is estimated to be appromiximately $ 2 billion, which is equvalent to 11% 
of the total farm milk sales(145).  It was previously demonstrated that intramammary 
injection of insect cell-derived recombinant bovine sCD14 (rbosCD14) is able to reduce 
the severity of inflammatory infection caused by E. coli in a mouse mastitis model as 
well as in lactating dairy cows (118, 119). This novel approach may be of critical 
importance in minimizing the impact of infections caused by Gram-negative bacteria.  As 
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CD14 is a protein found naturally in bovine milk (220) and is expressed on bovine 
macrophages (153), any side effects involving therapeutic applications of sCD14 should 
be minimal. 
 The goal of our study was to express the rbosCD14 protein in plants.  Plants 
represent one of the most plentiful and affordable sources for large, agricultural-scale 
production of biological products (131).  Taking into account the previously reported 
therapeutic effect of sCD14 against coliform mastitis (118, 119), expression of rbosCD14 
in plants and its purification was aimed at reducing the cost of production of rbosCD14 
for the treatment of mastitis in lactating dairy cows.  Unlike any other available means of 
CD14 manufacturing (bacterial and yeast cultures, insect cells), plants are inexpensive, 
offer animal and human pathogen-free biomass, and lack LPS. 
 
MATERIALS AND METHODS
Construction of prbosCD14, polymerase chain reaction (PCR) and reverse 
transcriptase (RT)-PCR. 
 The previously cloned cDNA encoding a truncated form of the CD14 ORF 
lacking 33 C-terminal amino acids (rbosCD14) (219) was amplified using the CD14-
specific sense primer LN53 5’GCGATATCAACAATGGTGTGCGTGCCCTACCT 
G and antisense primer LN54 5’GCGATATCTTATTAGTGATGGTGATGG 
TGATGC.  The LN54 primer contained the six HIS tag coding sequence present on the 
original clone.  EcoRV restriction sites were included on both primers for cloning 
purposes. Sense primer LN53 had an internal plant consensus sequence AACAATGG
which included the ATG initiation codon (bold) to modulate mRNA translational 
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efficiency in plants (Figure 9).  For detection of CD14 mRNA in plants, cDNA was 
synthesized from total RNA isolated from leaf tissue using TRI reagent (Molecular 
Research Center, Inc., Cincinnati, OH) and PCR amplified utilizing LN53/LN54 primers 
and Titan One RT-PCR Tube kit according to manufacturer’s directions (Roche 
Molecular Biochemicals, Indianapolis, IN).  
 
Cloning, in vitro transcription and plant inoculation 
PCR-amplified rbosCD14 was directly cloned into the TOPO 2 vector 
(Invitrogen, Carlsbad, CA) followed by subcloning into EcoRV-linearized plant virus 
expression vector PVX pP2C2S.  The integrity of all clones was verified by nucleotide 
sequencing (ABI-PRIZM 373A Genetic Analyzer, DNA sequencing facility, Center for 
Agricultural Biotechnology, University of Maryland, College Park, MD). Capped 
transcripts from recombinant PVX/CD14 virus were generated in vitro with RNA 
mMessage Machine T7 kit (Ambion, Austin, TX) and used to inoculate three top leaves 
of Nicotiana benthamiana plants. Inoculated plants were kept in a containment 
greenhouse facility at MPPL, USDA/ARS, Beltsville, MD. 
 
Purification and Western blotting analysis of plant-derived CD14 protein 
Histidine-containing the prbosCD14 was purified from plant extracts using a Ni-
NTA purification system (Invitrogen).  Leaf tissues were ground in liquid nitrogen and 
homogenized in PBS buffer containing a 1:100 dilution of protease inhibitor cocktail 
(Sigma).  The crude extracts were filtered through miracloth and, after two rounds of 
centrifugation (4,000 x g/20 min and 10,000 x g/20 min), cleared lysates were incubated 
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with 2 mL of Ni NTA resin for 2 h at 4VC and subsequently applied to 10 mL purification 
columns. Column resin was washed three times with 1 x PBS containing 20 mM 
imidazole.  Bound protein was eluted in 1 mL fractions with 1 x PBS containing 250 mM 
imidazole.  
 Crude plant extracts and purified proteins were analyzed by Western blotting 
using a 10-20% Tris-glycine gel according to manufacturer’s instructions (Invitrogen). 
Nitrocellulose membranes were probed with rabbit polyclonal antisera raised to 
rbosCD14 in a 1:1000 dilution overnight at 4VC following by 2 h incubation with a 
1:5000 dilution of goat anti-rabbit secondary antibody conjugated with alkaline 
phosphatase (Kirkegaard and Perry Laboratories, Gaithersburg, MD). Membranes were 
then developed with the BCIP/NBT Substrate System (Kirkegaard and Perry 
Laboratories). 
 
IL-8 ELISA 
Bovine aortic endothelial cells (generous gift of Dr. L.M. Sordillo, Michigan 
State University, East Lansing, MI) were seeded into 96-well plates at a density of 25,000 
cells/well and cultured for 24 h.  Following treatment, plates were centrifuged (220 x g,
10 min) and the supernatants analyzed using a commercially available kit for human IL-8 
(R&D Systems, Inc., Minneapolis, MN).  The antibody pairs used in this kit have been 
previously shown to cross-react with bovine IL-8 (192).  OD at 450 nm and a correction 
wavelength of 550 nm were measured on a microplate reader (Bio-Tec Instruments, Inc., 
Winooski, VT).  Values expressed in pg/mL were extrapolated from a standard curve of 
known amounts of human IL-8. 
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Endothelial injury/apoptosis assays.
For the determination of LPS-induced endothelial injury, endothelial cells were 
seeded into 96-well plates as above and monolayers were visualized on a Nikon Eclipse 
TE200 inverted phase-contrast microscope (Nikon, Inc., Melville, NY). LPS-induced 
endothelial injury was evidenced by cell rounding and detachment as previously reported 
(12).  For the specific assaying of apoptosis, endothelial caspase activity was measured 
with a fluorimetric homogenous caspases assay according to the manufacturer's 
instructions (Roche Molecular Biochemicals, Indianapolis, IN). The plates were analyzed 
on a fluorescence microplate reader (Bio-Tec Instruments) at 485 nm excitation and 530 
nm emission, and caspase activity expressed relative to simultaneous media controls.   
 
In vivo studies.
Clinically healthy Holstein cows, which were free of intramammary infections 
and had mammary quarter milk somatic cell counts (SCC) <200,000 cells/mL, were 
selected for the study.  To quantify somatic cells, milk samples were heated to 60°C and 
subsequently maintained at 40°C until counted on an automated cell counter (Fossomatic 
model 90, Foss Food Technology, Hillerod, Denmark) as previously described (141).  
Mammary quarters were infused with 0.3 Ng of LPS derived from E. coli 0111:B4 
(Sigma) dissolved in 10 mL of PBS or LPS pre-incubated (2 h at 37°C) with rbosCD14 
(100 Ng) in 10 mL of PBS.  Milk samples were collected at various time points and 
analyzed for MSCC.   
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Other studies were conducted to determine whether prbosCD14 could enhance 
bacterial clearance.  Prior to intramammary challenge, 10 mL of brain heart infusion 
broth (Becton-Dickinson Diagnostic Systems, Inc., Sparks, MD) were inoculated with E. 
coli strain P4 and incubated for 6 h at 37°C.  This strain was originally isolated from a 
clinical case of mastitis and has been used in other studies of mastitis (24, 25).  One 
milliliter of the incubated culture was transferred to an aerating flask containing 99 mL of 
tryptic soy broth (TSB) and incubated overnight at 37VC.  After incubation, the flask was 
placed in an ice water bath and mixed by swirling.  A 1 mL aliquot from the flask was 
serially diluted in PBS and 1 mL of the resulting dilutions mixed with 9 mL of pre-melted 
trypticase soy agar in petri dishes.  The plates were allowed to solidify at room 
temperature and then transferred to a 37VC incubator overnight.  The aerating flasks 
containing the stock cultures were maintained at 4°C overnight.  The concentration of the 
stock cultures was determined based on the prepared pour plates.  Immediately following 
the morning milking, quarters were infused with either 10 mL of PBS (n =3) or sCD14 
(100 µg) (n =3) followed by infusion of 75 CFU of E. coli suspended in 2 mL of PBS.  
Following challenge, aseptic milk samples were collected at various time points, serially 
diluted, and plated on blood agar plates.  Following a16 h incubation at 37 °C, colonies 
were enumerated.   
 
Statistical analysis.  
 For the analysis of in vitro studies, including IL-8 production and caspase activity, 
a one-way analysis of variance (ANOVA) was used to compare the mean responses 
among experimental groups using GraphPad Prism version 4.00 for Windows (GraphPad 
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Software).  For the in vivo studies comparing the effects of prbosCD14 on milk SCC and 
bacterial clearance, repeated measures ANOVA was performed using the PROC MIXED 
model (SAS 8.2; SAS Institute, Cary, NC).  For statistical analysis of milk SCC and 
bacterial CFU, data were transformed to log10 values.  A P-value of <0.05 was considered 
significant. 
 
RESULTS
Expression and purification of recombinant sCD14 in plants  
The truncated form of rbosCD14, lacking the last 33 aa at the carboxy terminus 
and encoding the N-terminal 358 amino acids of bovine CD14, and engineered to carry 
six histidine affinity residues for ease of purification (219), was modified to place the 
CD14 initiation codon in a “plant” consensus context of AACAATGG to increase the 
efficiency of mRNA translation in plants (125) (Figure 9).  In addition, an extra TAA 
termination codon was added to insure a proper translation termination (Figure 9).  The 
construct was placed under transcriptional control of the subgenomic coat protein 
promoter of the plant virus vector, Potato Virus X (PVX, 19) for transient expression in 
Nicotiana benthamiana. Plants were inoculated with in vitro synthesized, capped viral 
T7 RNA transcripts and tested for protein expression after showing systemic infection. 
Symptoms indicative of PVX infection were first visible as distinct vein clearing 
at 5-7 days post inoculation (dpi).  Plants eventually became systemically infected, 
developing symptoms indistinguishable from the wild type virus, including vein clearing, 
green mosaic, leaf curling and general stunting appearance within 10-14 dpi (data not 
shown).  No difference in timing or symptom expression was evident between plants 
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infected with PVX only and plants infected with PVX/CD14, indicating a potent 
infectivity of the recombinant virus. RT-PCR assay performed with CD14-specific 
primers confirmed the presence of CD14 mRNA, which was absent in the uninfected 
control plant as well as in plants inoculated with PVX only (data not shown). 
 
Western blotting analysis of recombinant protein from infected plants 
 Western blot analysis utilizing rbosCD14-specific polyclonal antibodies 
demonstrated that crude plant extracts as well as affinity-purified samples contained 
immunoreactive recombinant protein of predicted molecular mass, though slightly 
different in appearance compared to rbosCD14 produced in insect cells (Figure 10).  The 
concentration of prbosCD14, determined by CD14-specific ELISA, varied from 15-20 µg 
to approximately 300-500 µg/mL of affinity-purified pure recombinant protein 
preparation (data not shown).  The purifed prbosCD14 did not contain LPS. 
From the results of multiple Western blotting experiments, recombinant protein 
concentrations in primary-inoculated plants remained stable for about three weeks p.i. 
and then declined gradually.  A passage of infection within this period led to a 
comparable protein expression level in secondary-inoculated plants during the same time 
interval.  Transmission of virus and/or testing of protein at late stages of infection 
resulted in significantly lower expression apparently due to a loss of CD14 sequence and 
reversal of recombinant virus to the original PVX wild-type genomic sequence. 
 
Plant rbosCD14 is a fully functional molecule that can promote LPS signaling.
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 Cells lacking mCD14, including endothelial cells, require sCD14 for 
recognition of and activation by LPS.  To determine whether plant rbosCD14 could 
functionally promote cellular activation by LPS, endothelial cells were washed three 
times with serum-free media and treated with either PBS or LPS (100 ng/mL) in the 
presence of serum-free media containing 250 ng/mL of prbosCD14.  This concentration 
of prbosCD14 was able to promote LPS-induced IL-8 production to a comparable degree 
as that of insect cell-derived rbosCD14 or endogenous sCD14 found in bovine serum 
(Figure 11A).  Exposure to prbosCD14 alone had no effect on endothelial IL-8 
production.  Consistent with a requirement for sCD14 for activation, LPS did not induce 
IL-8 production in the absence of sCD14 (i,e, serum-free media).  The ability of plant 
rbosCD14 to promote LPS-induced IL-8 production was dose-dependent and 
concentrations as low as 10 ng/mL were able to elicit this response (Figure 11B). 
 In addition to the induction of IL-8, LPS is reported to induce endothelial injury 
and apoptosis.  Whereas IL-8 production is mediated through the NF-QB signaling 
pathway, LPS-evoked pro-apoptotic signaling occurs through an NF-QB-independent 
pathway (13).  To determine whether prbosCD14 could promote LPS signaling through 
this NF-QB-independent pathway, endothelial cells were treated as above and assayed 
biochemically for caspase activation, an indicator of apoptosis (Figure 11C) and visually 
for evidence of injury (Figure 12).  Similar to IL-8 production, prbosCD14 was able to 
promote LPS-induced apoptosis and injury to a similar extent as that of endogenous 
sCD14 found in bovine serum or insect cell-derived rbosCD14. 
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Plant rbosCD14 enhances LPS-induced milk SCC and promotes clearance of E. coli 
in vivo 
Previous studies have established the ability of sCD14 to enhance host responses 
to bacterial LPS.  LPS has been demonstrated to induce an acute inflammatory response 
in the mammary glands of cows that is characterized by an increase in milk somatic cells, 
greater than 90% of which are PMN.  To determine whether prbosCD14 could enhance 
PMN recruitment as indicated by increased milk somatic cell counts, 0.3 Ng of LPS was 
infused into the quarters of lactating dairy cattle in combination with either PBS or 
sCD14 (100 µg).  Initial studies established that intramammary infusion of saline or 
prbosCD14 alone had no effect on milk somatic cell counts (data not shown), similar to 
results obtained for insect cell-derived rbosCD14 (219).  LPS elicited an increase in milk 
SCC and this response was enhanced by prbosCD14 (Figure 13).  The overall significant 
difference between the two treatment groups (P = 0.0121) is comparable with results 
obtained using insect cell-derived rbosCD14 (117, 219). 
 In addition to its ability to enhance the responses to LPS, CD14 has been 
demonstrated to facilitate E. coli clearance (119).  To determine whether prbosCD14 
could similarly enhance bacterial clearance, mammary glands were infused with either 
saline or prbosCD14 (100 µg), and subsequently infused with 75 CFU of E. coli. There 
was an overall significant decrease (P = 0.0265) in the number of viable E. coli recovered 
from quarters infused with prbosCD14 compared with those receiving saline (Figure 14), 
and an absence of clinical symptoms (not shown).  In addition, there were no obvious 
adverse effects of the engineered protein carrying the histidine tag in either the in vitro or 
in vivo tests.  
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DISCUSSION
This study provides evidence, for the first time, that a functional animal receptor 
protein can successfully be produced in plants by transient expression from a potex virus 
vector.  A number of biopharmaceuticals, including vaccines and therapeutic proteins, 
have been expressed in plants (132, 207), the primary motivation being the expression of 
potentially effective and useful proteins of non-plant origin in a plant system.  Many 
reports have demonstrated the suitability of plants as vehicles for synthesizing particular 
proteins; however, follow-up studies of the biological activity of the recombinant protein 
in the targeted host animal and subsequent disease challenge are less common.  The 
objective of our study was not only to achieve plant expression of the bovine CD14 
receptor, but also to demonstrate the application of the plant-produced CD14 in the 
treatment of intramammary bacterial infection of dairy cows.  
 The expression of the truncated, histidine-tagged, sCD14 in plants infected with 
the recombinant PVX virus was stable for several weeks; however, instability of the virus 
construct occurred upon subsequent passage to new plants.  ELISA tests designed to 
measure affinity purified CD14 resulted in estimates of 10-20 µg/mL and up to 300-500 
µg/mL of purified CD14.  On average, the results indicate at least a 10-fold smaller 
concentration, between 1-10 µg/gm fresh weight tissue, or roughly 0.125 % total soluble 
protein.  It is not known what contributes to this discrepancy in values, although variable 
efficiency of affinity purification to obtain the final product may contribute.  The estimate 
of 20 µg/mL of purified CD14 was used to calculate amounts of prbosCD14 for 
subsequent in vitro and in vivo tests. 
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 The protective effect of rbosCD14 produced in a baculovirus expression system 
was previously demonstrated in a mouse model and in lactating dairy cows (117, 118). 
Our findings indicate that prbosCD14 is a biologically active protein, possessing 
characteristics similar to rbosCD14.  Endothelial cells lacking mCD14 can only respond 
to LPS in the presence of sCD14.  In the presence of prbosCD14, LPS induced apoptosis, 
caspase activity, and IL-8 production in bovine endothelial cells, demonstrating the 
capability of prbosCD14 to complex with LPS and mediate LPS-induced cell activation. 
Leukocyte recruitment from the blood to the mammary gland is an important component 
in the defense response of the host against intra-mammary infections.  In vivo, 
prbosCD14 enhanced LPS-induced recruitment of leukocytes to the mammary glands.  
 After functional activity of prbosCD14 was confirmed in vitro using epithelial 
cell culture and in vivo by intramammary injection of LPS, the protective effect of 
prbosCD14 was tested in a bovine mastitis model.  Infusion of prbosCD14 into E. coli-
challenged mammary glands significantly reduced the number of viable bacteria 
recovered relative to quarters infused with E. coli and saline.  In addition, there was an 
absence of clinical symptoms in prbosCD14/E. coli quarters in contrast to saline/E. coli 
quarters indicating a protective effect of the plant-produced protein. 
 Mastitis continues to be the most costly disease in animal agriculture.  Currently, 
treatment of coliform mastitis caused by Gram-negative bacteria, which are responsible 
for the majority of the cases of clinical mastitis, remains sub-optimal.  Thus, the lack of 
effective control measures reinforces the urgent need to develop new therapeutic 
modalities.  Results reported in this study suggest that probsCD14 can be a potent tool in 
minimizing the impact of infections caused by Gram-negative bacteria.  
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Figure 9. Structure of the truncated rbosCD14, lacking the 33 3’terminal amino acids, 
incorporated into the PVX pP2C2S vector. The ATG codon was placed in the 
surrounding plant translational consensus sequence (bold); an extra TAA stop codon was 
introduced at the 3’ terminus (bold). The construct also contains the exons for six 
histidine residues (underlined). Transcription of sCD14 is driven by the duplicated coat 
protein (CP) subgenomic promoter located upstream of the open reading frame (ORF) 5 
CP. Also indicated on the linear map are the locations of the ORF 1 RdRp (replicase), 
ORF2, ORF3 and ORF 4 of the triple gene block of PVX.  
 
ORF1 RdRP     ORF2
ORF3
ORF4 ORF5 CP
TGB sgRNA
CP sgRNA 
AACAATGGTGTGCGTGCCCTACCTGCTGCTGCTGCTGCTGCCGTCACTGC
TGCGTGTGTCTGCGGACACAACAGAACCCTGCaAGCTGGACGACGACGAT
TTCCGTTGTGTCTGCAACTTCACGGATCCGAAGCCTGACTGGTCTAGCGC
CGTTCAGTGTATGGTTGCCGTCGAGGTGGAGATCAGTGCCGGCGGCCGCA
GCCTGGAACAGTTTCTCAAGGGAGCCGACACCAACCCGAAGCAGTATGCT
GACACAATCAAGGCTCTGCGCGTTCGGCGACTCAAGCTGGGCGCTGCACA
GGTTCCTGCTCAGCTTCTGGTCGCCGTTCTGCGCGCGCTCGGGTACTCTC
GTCTCAAGGAACTGACGCTTGAGGACCTGGAGGTAACCGGCCCAACGCCC
CCGACGCCTCTGGAAGCCGCTGGGCCTGCGCTCACCACCCTCAGTCTCCG
TAACGTATCGTGGACAACAGGAGGTGCCTGGCTCGGCGAACTGCAGCAGT
GGCTCAAGCCTGGGCTCAGGGTGCTGAACATTGCCCAAGCACACTCGCTT
GCCTTTCCGTGCGCAGGGCTCTCCACCTTCGAGGCGCTCACCACCCTAGA
CCTGTCTGACAATCCCAGTCTCGGCGACAgcGGGCTGATGGCAGCTCTCT
GTCCGAACAAGTTCCCGGCCCTCCAATATCTAGCGCTACGCAACGCGGGG
ATGGAGACGCCGAGCGGCGTGTGCGCGGCGCTGGCGGCAGCGAGGGTGCA
GCCCCAAAGCCTGGACCTCAGCCACAACTCGCTGCGCGTCACCGCCCCGG
GTGCTACCCGATGTGTCTGGCCCAGTGCACTAAGGTCTCTCAATTTGTCG
TTCGCTGGGCTGGAGCAAGTGCCTAAGGGACTGCCCCCTAAGCTCAGCGT
GCTTGATCTCAGCTGCAACAAGCTAAGCAGGGAGCCaCGGcGAGACGAGC
TGCCCGAGGTAAATGACCTGACTCTGGACGGAAATCCCTTTCTGGACCCT
GGAGCCCTCCAGCACCAAAATGACCCCATGGGGCATCACCATCACCATCA
CTAATAA 
pP2C2S 
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5 4 3 2 1 M
Figure 10.  Western blotting analysis of samples from PVX/CD14-infected plants, 
probed with CD14-specific polyclonal antisera. M, Protein marker (New England 
BioLab). 1, CD14 positive control, ~46 kDa, ~200 ng/load; 2, PVX/CD14-infected plant; 
3 and 4, plant infected with PVX only; 5, non-infected plant 
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Figure 11.  Effect of plant-derived rbosCD14 on LPS-induced IL-8 production and 
caspase activation.  Bovine aortic endothelial cells were exposed to PBS or LPS (100 
ng/mL) for 16 h in the presence or absence of serum, or in serum-free media containing 
insect cell- or plant-derived rbosCD14 (250 ng/mL) (A, C). In other experiments, 
endothelial cells were exposed to LPS (100 ng/mL) in serum-free media containing 
increasing concentrations of plant-derived rbosCD14 (B). Vertical bars represent mean 
(+S.E.) IL-8 production expressed in pg/mL (A, B) or mean caspase activity expressed 
relative to simultaneous PBS controls (C). * = Significantly increased compared to 
endothelial cells exposed to LPS in serum-free media (P<0.05). 
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Figure 12. Effect of plant-derived rbosCD14 on apoptosis on endothelial cells. 
Bovine aortic endothelial cells were exposed for 16h (A) in the serum free media with 
PBS, (B) in the serum free media with LPS (100 ng/mL), (C) in the media containing 
serum with PBS,  (D) in the media containing serum with of LPS (100 ng/mL), (E) in the 
media containing PBS with insect cell-derived rbosCD14 (250 ng/mL), (F) in the media 
containing LPS (100 ng/mL) with insect cell-derived rbosCD14 (250 ng/mL), (G) in the 
media containing PBS with plant-derived rbosCD14 (250 ng/mL), (H) in the media 
containing LPS (100 ng/mL) with  plant-derived rbosCD14 (250 ng/mL). 
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Figure 13. Effect of plant-derived rbosCD14 on LPS-induced increases in milk somatic 
cell counts (SCC).  Three glands were infused with LPS (0.3 µg) or a combination of LPS 
and plant-derived rbosCD14 (100 µg).  Milk samples were collected immediately prior to 
(time 0) and at various time points following infusion and analyzed for milk SCC.  Mean 
(+ S.E.) milk somatic cell counts are reported in thousands/mL. 
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Figure 14. Effect of plant-derived rbosCD14 on E. coli intramammary viability.  Three 
glands were infused with either saline or plant rbosCD14 (100 µg) and subsequently 
infused with 75 CFU of E. coli. Milk samples were collected aseptically immediately 
prior to (time 0) and at various time points following infusion and plated for the 
enumeration of viable bacteria.  The mean (+ S.E.) of log10 CFU/mL is shown. 
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Chapter Four: Shedding of sCD14 by Bovine Neutrophils Following 
Activation with LPS Results in Down-Regulation of IL-8 
 
ABSTRACT
The expression of CD14 on the surface of PMN increases after exposure to some 
inflammatory stimuli such as N-formyl-methionyl-leucyl-phenylalanine (fMLP). These 
newly expressed molecules probably originate from an intracellular pool of preformed 
receptors.  We sought to characterize bovine PMN cell surface expression and shedding 
of CD14 molecules and its effect on secretion of IL-8 by PMN.  Bovine PMN were 
incubated in RPMI for 20 h at 37°C with LPS (1,10, and100 µg/mL) in the presence or 
absence of 5% FBS.  The culture supernatant was assayed for IL-8 and sCD14 by ELISA.  
At 20 h, IL-8 release decreased 41.5 and 95% in the absence of FBS, and 4.3 and 35.5%, 
respectively in the presence of FBS at the 10 and 100 µg/mL of LPS compared to the 1 
µg/mL of LPS.  Shedding of CD14 from the surface of PMN increased in the absence of 
FBS at the highest concentration of LPS (100 µg/mL).  The use of real time polymerase 
chain reaction showed that CD14 mRNA was not different between control and LPS 
stimulated cells after 1 h, suggesting that the sCD14 came from membrane-boundCD14 
(mCD14).  Bovine PMN apoptosis, as determined with annexin-V, was induced in the 
presence of FBS, and was slightly inhibited in the absence of FBS after 6 h of incubation 
with all concentrations of LPS.  CD18 expression was up-regulated with different 
concentrations of LPS, but the shedding of L-selectin increased with increasing cell 
density.  Secretion of PGE2 decreased in a LPS dose-dependent manner in the absence of 
serum, and increased in a LPS dose-dependent manner in the presence of serum and with 
increasing cell density.  The shedding of CD14 by PMN increased at 6 h and then slowly 
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decreased until 20 h.  Shedding of CD14 by PMN after exposure to LPS increased 93%, 
and secretion of IL-8 decreased 93% at a cell density of 10 x 107 PMN/mL of PMN.  
Secretion of IL-8 from PMN was not detected at 6 h and IL-8 secretion decreased at high 
concentrations of LPS.  The secretion of IL-8 was reduced in RPMI media without FBS 
compared to media with FBS.  Our results demonstrate the release of CD14 from the 
surface of PMN in response to LPS, that IL-8 production was suppressed by LPS and that 
sCD14 in the absence of FBS was more effective in suppressing secretion of IL-8 than in 
the presence of FBS. 
 
INTRODUCTION 
The recruitment and activation of polymorphonuclear neutrophil leukocytes 
(PMN) are important for nonspecific host defense against infectious agents.  PMN are 
short-lived blood cells that play a vital role in the inflammatory response.  They are one 
of the first cells recruited to the site of injury or infection.  PMN activation results in 
increased phagocytosis, bacterial killing, release of lysosomal enzymes, and generation of 
superoxide anion (223).  A number of exogenous and endogenous peptide and lipid 
mediators, such as fMLP, C5a, leukotriene B4 and cytokines are chemoattracts for PMN 
and are referred to as chemokines (8).  IL-8 is the best characterized among the PMN 
attracting chemokines.  IL-8 belongs to the CXC family of chemokines, and simulates 
PMN adherence, degranulation, respiratory burst, and lipid mediator synthesis (160).  
Human PMN have been reported to synthesize IL-8, TNF-?, IL-1B, macrophage-colony 
stimulating factor (m-CSF), and granulocytes-CSF (G-CSF), as well as an IL-1 receptor 
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antagonist (36).  Activated PMN express many molecules on their cell surfaces (143) and 
release soluble factors such as cytokines (33) and proteases (223).   
Many functionally important receptors for microbial ligands have not yet been 
identified on PMN (138).  TLRs have been identified on mammalian monocytes and 
PMN.  TLRs mediate cellular responses to a large array of microbial ligands.  TLR2 is 
the receptor for a variety of microbial ligands, including Gram-positive bacteria, 
peptidoglycan and zymosan.  TLR4 is a receptor for Gram-negative bacteria and LPS.  
TLR4 and TLR2, like other TLR family members, have a conserved intracellular 
signaling motif.  TLR4 and LBP activate the intracellular signaling pathways in PMN 
(189).  TLR4 and CD11b/CD18 are the other key receptors that bind to LPS, and activate 
the intracellular signaling pathways in PMN (175). 
The other important receptor for a microbial ligand is CD14.  CD14 is GPI-
anchored protein expressed at high levels on the surface of circulating monocytes and 
macrophages.  PMN contain an intracellular pool of CD14 found in azurophile granules 
(174).  sCD14 which is present in serum, is also present in both the plasma membrane-
secretory vesicles of human PMN (174).  mCD14 and sCD14 function as co-receptors for 
microbial ligands.  sCD14 can neutralize LPS-LBP complexs, thus preventing over 
stimulation of the inflammatory response (129, 183) and can insert into the plasma 
membrane of cells that do not express CD14 such as endothelial cells and stimulate 
release of cytokines (75). 
Prostaglandins are multipotential mediators in many biological responses.   In 
Gram-negative infection, they play a major role in the inflammatory responses (62). 
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Recently, cytokines released by human PMN have been characterized, but have 
not been characterized for bovine PMN.  Our study demonstrates that down-regulation of 
IL-8 secretion by bovine PMN after LPS stimulation is sCD14 dependent, and involves 
PGE2, L-selectin, and CD18.  We also report that sCD14 is shed from the surface of 
bovine PMN and not from an intracellular pool as determined by RT-PCR. 
 
MATERIALS AND METHODS
Animals 
 Sixteen clinically normal pregnant mid- to late-lactating Holstein cows (220 ± 60 
days in milk) were used.   
 
Blood sampling and PMN isolation 
 
Blood was collected from the tail vein by venipuncture in heparinized vacutainer 
tubes.  Blood was centrifuged at 500 x g for 5 min at 4VC.  Plasma, buffy coat, and 1/3 of 
the red blood cells were removed.  The pellet in the remaining blood was suspended 
dropwise into a double volume of cold 0.2 % NaCl solution and gently mixed for about 1 
min for lysis red of blood cells.  Immediately, half the original volume of 3.7 % cold 
NaCl solution was added to restore isotonicity.  The suspension was centrifuged for 1min 
at 200 x g at 4°C and the pellet was washed twice with 20 mL of PBS.  Smears were 
prepared from the pellet and stained with Hemacolor (Merck, D-64293 Darmstadt 1, 
Germany). Differential microscopic counts were determined by counting 100 cells.  
Purity of the isolated PMN was 94 %. 
 
Cell culture and stimulation studies 
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 For cell density studies, PMN were resuspended in RPMI either with or without 
heat inactivated (560C, 30 min) 5% FBS and plated onto 96-well tissue culture plates at 1 
x 107, 5 x 107 and 10 x 107 PMN/mL (200 µL/well) containing 0, 0.1 and 10 Ng/mL of 
LPS, and incubated at 37VC for 16 h in a 5% CO2 incubator.  PMN (5 x 106 PMN/mL) 
were cultured with media alone (control) or stimulated with 1, 10, 100 µg/mL of LPS for 
either 6 or 20 h at 37VC.  Cells and cell supernatants were separated by centrifugation at 
500 x g and supernatants were stored at -20°C until further processing.  
 
Apoptosis of PMN isolated from blood 
 After stimulation of PMN for 6 or 20 h at 37oC with the various concentrations of 
LPS in the presence or absence of heat inactivated 5% FBS, apoptosis was quantified 
using a dual-color flow cytometric procedure with staining of phosphatidylserine by 
Annexin-V-FLUOS staining kit (Roche, Penzberg, Germany). 
Flow cytometric analysis  
 
One million PMN were incubated with different concentrations of LPS for 20 h 
and reacted at 4°C for 30 min with either anti-rbosCD14 mAb (198) (1:10), anti-CD18 
mAb (1:100), L-selectin mAb (220)(1:1 and 1:100) or PBS (control).  The cells were 
washed 3 x with PBS.  FITC-labeled affinity-purified antibody to mouse IgG +IgM 
(H+L) (KPL Inc) was added to the cells at a 1:100 dilution in PBS.  After 30 min of 
incubation at 4 °C, the wells were washed 3 x with PBS and resuspended in 200 µL PBS.  
Flow cytometric analysis was performed using a Coulter Epics Profile I-Argon laser flow 
cytometer (Coulter Electronics Inc).     
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cDNA synthesis and real time reverse transcription-PCR 
PMN (5 x 107) were seeded into each of 96 wells and incubated for 1 h at 37°C in 
RPMI1640 in the presence or absence of 5% heat inactivated FBS with 1 or 10 µg/mL of 
LPS.  Total RNA was extracted from cells using the Rneasy mini kit (Qiagen Inc., 
Valencia, CA, USA).  RNA quantity and quality were determined using a 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA). 
Reverse transcrption was conducted using 150 ng of total RNA and the iScript cDNA 
Synthesis kit (Bio-Rad Laboratories, Hercules, CA, USA) in a 20 µL reaction volume 
accorindg to kit instruction.  For each reaction, a parallel negative control reaction was 
performed in the absence of reverse transcriptase.  The subsequent PCR reactions were 
conducted in duplicate iQ SYBR Green Supermix (Bio-Rad Laboratories) using 2 µL of 
cDNA and 1 µM each primer, in a 25 µL reaction volume.  The primer sequences were: 5’-
CTCCAGCACCAAAATGAC-3’ (forward) and 5’-TCCTCTTCCCTCTCTTCC-3’ 
(reverse).  Cycling conditions was performed in the iCycler iQ detection system (Bio-rad 
Laboratories) using the following conditions: 95VC for 3 min, followed by 45 cycles of 15s at 
94VC, and 30s at 54 VC and 30s at 72VC.  Identification of the 145-bp amplification products 
was confirmed by direct sequencing using a CEO8000 automated sequencer and DTCS 
Quickstart chemistry (Beckman Coulter, Inc., Fullerton, CA, USA).  Quantification of 
samples was conducted using the iCyler Software from an external standard calibration curve 
analyzed simultaneously. Standards were synthesized from gel-purified CD14 PCR 
amplification products and ranged from 100 to 1 x 107 copies.  Efficiency of amplication for 
all assays was >95.9% and the correlation coefficient was > 0.99%. 
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Soluble CD14 ELISA  
Flat-bottom 96-well plates were coated with 5 Ng/mL of mouse anti-rbos CD14 
mAb (CAM36A clone; VMRD, Inc., Pullman, WA) diluted in 0.05 M sodium carbonate, 
pH 9.6 at 4 °C.  The plates were washed 4 x with 0.05% Tween 20 diluted in 50 mM 
TBS, pH 8.0, and subsequently blocked with 2% fish skin gelatin (Sigma) for 1 h at room 
temperature.  Plates were washed and 100 µL of supernatant samples was added to each 
well and incubated for 2 h at room temperature and was washed 3 x with TBS.  Rabbit 
anti-bovine CD14 polyclonal antibody (198) was diluted 1:2000 in TBS buffer containing 
0.2% gelatin, and 100 µL was added to each well and subsequently was washed as above.  
One-hundred µL of HRP-conjugated goat anti-rabbit IgG (H+L; Promega) diluted in PBS 
containing 0.2% gelatin (1:5000) was added to each well.  Plates were incubated for 1 h 
at room temperature, washed as above, and 100 µL of TMB substrate solution was added 
to each well.  The reaction was stopped by the addition of 50 µL of 2 N H2SO4 and the 
absorbance read at 450 nm on a microplate reader (Bio-Tek Instruments).   
IL-8 production  
PMN were stimulated with different concentrations of LPS for 20 h and at 
different cell desntiy with 0.1 and 100 ng/mL of LPS.  Supernatants were assayed for IL-
8 with a commercially available human IL-8 ELISA kit (R&D Systems).   
PGE2 production 
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PMN supernatants were assayed for PGE2 using a commercially available multi-
species prostaglandin E2 competitive ELISA kit (Endogen). 
 
Statistical methods 
 The unpaired or paired sample t-test and ANOVA (Prism version 4.0 for 
Windows; GraphPad Software Inc.) were used for the statistical analysis; P values below 
0.05% were considered significant.
RESULTS
Apoptosis of PMN 
Apoptosis of bovine PMN was suppressed (P < 0.05) after 6 h of stimulation with 
all concentrations of LPS in the absence of FBS (Figure 15).  In contrast, in the presence 
of FBS, apoptosis of bovine PMN was increased (P < 0.05) after 6 h of stimulation with 
all concentrations of LPS (Figure 15).  After exposure of PMN for 20 h to all 
concentrations of LPS (1, 10 and 100 µg/mL) in the presence or absence of FBS, no 
effect was observed on apoptosis (P>0.05) when compared to PMN in media alone ( 
Figure 16). 
 
Surface CD14 receptor expression    
We examined the expression of mCD14 on PMN in the absence or presence of 
5% FBS.  The percentage of PMN expressing mCD14 without LPS treatment was 35.6 ±
2.6 % in the absence FBS, and 29.9 ± 0.4% in the presene of FBS.   The percentage of 
PMN expressing mCD14 was significantly decreased (P<0.001) after stimulation with 
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100 µg/mL of LPS in the absence of FBS (Figure 17A).  In the presence of FBS, the 
percentage of cells fluorescing significantly increased (P<0.001) at 1 µg/mL of LPS, and 
did not differ with treatment of 10 or 100 µg/mL of LPS (Figure 17B).  There were no 
changes in the LMFC among the various treatments (data not shown).  
 
Expression of mRNA CD14  
 Expression of CD14 mRNA in bovine PMN was studied by real time RT-PCR.  
We observed that there was no increase in the mRNA expression levels of CD14 mRNA 
when the PMN were exposed for 1 h to all concentrations of LPS treated, in the presence 
or absence of FBS when compared with the mRNA expression levels for control PMN 
(Figure 18). In the absence of FBS, mRNA expression of CD14 was less when compared 
to mRNA expression obtained in the presence of FBS, but the differences were not 
significant (P>0.05). 
 
Expression of CD18 on PMN 
Granule exocytosis is an important function of activated PMN.  During this 
process, the granule membrane incorporates into the cell membrane and increases 
expression of granule-membrane markers such as CD11b and CD18 (186).  The 
expression of CD18 on PMN in the absence or presence of 5% FBS with different 
concentrations of LPS (1, 10 and 100 µg/mL) at 20 h was examined.  CD18 by flow 
cytometry was significantly up-regulated (P<0.05) for all concentrations of LPS-induced 
when compared to control value (Figure 19). 
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Secretion of sCD14 after LPS stimulation  
In the absence of 5% FBS, PMN exhibited a significant release (P< 0.05) of 
sCD14 in response to 100 µg/mL of LPS relative to control PMN after 20 h of incubation 
(Figure 20A).  In the presence of FBS, the release of sCD14 was greater (P < 0.01) when 
compared to values obtained in the absence of FBS, but significant differences among 
various concentrations of LPS-induced were not detected (P > 0.05) (Figure 20B).  
Release of sCD14 from PMN after LPS stimulation (100 µg/mL) was increased overtime 
in the presence of FBS (Figure 21A), but was decreased by 16 and, 23% at 16 and 20 h, 
respectively in the absence of FBS when compared to sCD14 release at 6 h (Figure 21B).  
 
Secretion of IL-8 after LPS stimulation 
 To investigate secretion of IL-8, PMN were incubated with different 
concentrations of LPS (1,10, or 100 µg/mL) in either the absence or presence of 5% FBS.  
IL-8 secretion from PMN did not reach detectable levels until 6 h after LPS stimulation 
(Data not shown).  IL-8 secretion from PMN was the highest at the concentration of LPS 
(1 µg/mL) in the absence (670.4 ± 210.2 pg/mL) or presence (734 ± 205.7 pg/mL) of 5% 
FBS.  Incubation of PMN with 10 and 100 µg/mL of LPS decreased IL-8 secretion by 
41.5 and 95 %, respectively in the absence of FBS, and by 4.3 and 35.5%, respectively in 
the presence of FBS when compared to treatment with 1 µg/mL of LPS (Figure 22A, 
Figure 22B). 
 
Effect of cell density on secretion of sCD14 and IL-8 
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Media at varying cell densities (10 x 107, 5 x 107, 2.5 x 107, 1 x 107 PMN/mL)  
were obtained after 16 h incubation with 0.1 and 10 µg/mL of LPS at 37VC.  As depicted 
in Figure 23A, secretion of sCD14 after stimulation with 10 Ng/mL of LPS increased at 
the higher cell densities when compared to a cell density of 1 x 107 PMN/mL (P<0.001).  
The increase in sCD14 was inversely related to release of IL-8 from PMN (Figure 23B).  
The same inhibitory effect of sCD14 on IL-8 release was also observed when PMN were 
stimulated with 0.1 µg/mL of LPS (Figure 24A and 24B).  
 
PGE2 release from PMN after LPS stimulation 
 In the absence of FBS, all concentrations of LPS induced the secretion of PGE2
from PMN (P<0.05) (Figure 25A).  The secretion was greatest at 1 µg/mL of LPS, and 
decreased by 13.6 and 56.4% at 10 and 100 µg/mL of LPS, respectively (Figure 25A).  In 
the presence of FBS, PGE2 was secreted at 2-fold higher concentrations than was 
observed in the absence of FBS.  At concentrations of 1,10 and 100 µg/mL of LPS, PGE2
averaged (230 ± 25.4, 275 ±15.8, 275 ± 48.2 pg/mL) (Figure 25B).  The secretion of 
PGE2 increased by 57 and 42% at cell concentrations of 10 x 107 and 5 x 107 cells/mL 
when compared to densities of 2.5 x 107 and 1 x 107 cells/mL of PMN (Figure 25C). 
 
L-selectin shedding from enhanced cell density  
 In the absence of FBS, L-selectin expression on PMN was up-regulated with 
treatment of 1 µg/mL of LPS when compared to media control (P<0.05) and did not 
differ from control at 10 and 100 µg/mL of LPS (Figure 26A).  Treatment with LPS had 
no effect (P > 0.05) on expression of L-selectin when compared to media control in the 
76
presence of FBS.  The expression of L-selectin decreased (P<0.05) at 10, 5 and 2.5 x 
107cells/mL PMN compared to expression at 0.5 x 107/mL PMN when PMN were 
incubated with 0.1 µg/mL LPS for 20 h (Figure 26B).  
 
DISCUSSION
In our experiment, we observed that LPS delayed apoptosis in the absence of FBS, 
and that the presence of FBS had no effect on apoptosis of PMN.  Because 30% the 
isolated PMN used in this study expressed mCD14, they were able to respond to LPS in 
the absence of FBS.  In the presence of FBS, the sCD14 in the serum may have bound the 
LPS making it unavailable to the PMN, resulting in a failed anti-apoptotic response.  LPS 
was found to delay apoptosis in isolated human PMN (116, 222).  In contrast, using 
whole blood, Oostveldt (238) reported that LPS accelerated bovine PMN apoptosis.  
Interestingly, PMN apoptosis was induced following intramammary challenge with E. 
coli, but no effect was observed following intramammary injection of (236).  The author 
attributed this to the appearance of TNF-?, an inducer of apoptosis, in blood after 
challenge with E. col that was not present in blood after challenge with LPS.   
TLRs are a class of receptors that recognize pathogen-associated molecules.  
TLR2 and TLR4 recognize LPS (229).  These receptors are found on a variety of cell 
types including PMN.  The binding of LPS to TLR is facilitated by CD14 (227).  A study 
by Yang (229) reported that TLR2 is a signaling receptor that is activated by LPS and is 
dependent on LPS binding protein.  From these experiments, we hypothesize that in the 
absence of serum, LPS can affect the TLR pathway and activate the scavenger receptor 
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pathway.  The scavenger receptor CD36 functions as a co-receptor, acting in conjunction 
with TLR2, and recognizes LPS (41).  
A significant finding from the present study is that mCD14 is expressed on bovine 
PMN, and that sCD14 comes from the shedding of mCD14 from bovine PMN and is 
accelerated after LPS stimulation.  These findings are supported by studies that reported 
high mCD14 expression levels are on peripheral monocytes and intestinal macrophages 
derived from patients with Crohn’s disease and inflammatory bowel disease (78) and that 
mCD14-positive PMN accumulate in the lungs of patients with acute respiratory distress 
syndrome.  In contrast, circulating PMN exhibits low mCD14 expression due to its 
shedding from the cell surfaces of stimulated PMN from patients with acute respiratory 
distress syndrome (157).  The increase in sCD14 was suggested to be associated with the 
accumulation of PMN at inflammatory sites (37, 118).  The level of sCD14 was found to 
be strongly related to the concentration of PMN in the bronchoalveolar lavage from 
patients with acute lung injury (135) and in milk of cows containing high concentrations 
of PMN (118).  LPS-induced the release of CD14 from human PMN, and was suggested 
to originate from the shedding of mCD14 and from an intracellular pool stored in the 
granules of PMN (53, 174).  In our study LPS caused the percentage of PMN expressing 
mCD14 to decrease that resulted in increase in sCD14 at the highest concentration of LPS 
in the absence of FBS.  Our study also showed that bovine PMN have an intracellular 
pool of CD14, and that mRNA CD14 expression did not increase after LPS stimulation.  
This result indicates that the source of the sCD14 may be mCD14.  sCD14 found in 
human serum has been attributed to the shedding of mCD14 from monocytes, 
macrophages and PMN (59).  A study by Paape et al (153) reported that bovine PMN 
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expressed mCD14 after migration into the mammary gland or after overnight incubation 
of isolated circulating PMN in milk.   
 Other significant observations to emerge from the present study were that IL-8 is 
secreted by bovine PMN, and that the release of sCD14 from PMN may cause down-
regulation of IL-8 secretion from PMN.  sCD14 secretion of LPS-treated PMN was 
increased in parallel with the decrease in IL-8 secretion (Figure 20A, Figure 22A).  
Further, the increase of sCD14 with increasing concentrations of PMN after LPS 
stimulation was also in parallel with the decrease of IL-8 (Figure 23, Figure 24).  It was 
reported that production of IL-8 was inhibited via CD14 cleavage by human leukocyte 
elastase, which might be another mechanism for the down-regulatory cascade of 
inflammation (146).  Burkholderia cepacia induced IL-8 synthesis in human lung 
epithelial cells in a CD14 and mitogen activated protein kinase dependent manner (169).  
A study by Katja Hattar (86) reported that IL-8 synthesis and release were dramatically 
reduced at high PMN density.  This negative feedback mechanism reported in this and 
other studies is to be assumed to result in the inhibition of further PMN recruitment and 
activation and contributes to the control of inflammatory functions in vivo. Generation of 
IL-8 from PMN was previously shown to be regulated a wide variety of soluble agonists 
such as IL-4, IL-10, IL-13 and INF-C (102,137, 224) and IL-1 and TNF-? receptors (86).   
Our study demonstrated that the absence or presence of FBS influenced the 
release of CD14, IL-8 and the expression of mCD14.  We assume that protease inhibitors 
from serum should affect the release of sCD14, IL-8 and expression of mCD14.   
 We demonstrated that there was a dose-dependent decrease in the induction of 
PGE2 in PMN stimulated with LPS, and that PGE2 was continuously secreted from PMN 
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at increased cell densities.  It has been suggested that PGE2 may be involved in LPS-
induced septic shock through up-regulation of inflammatory cytokines via CD14 (93).  
This is in agreement with our study where sCD14 and PGE2 are continuously secreted at 
high concentrations of PMN stimulated with LPS.   
 Bovine PMN adhesion molecules such as L-selectin (CD62L) and the beta2 -
integrins (CD18) play a key role in the initial contact and in the subsequent strong 
adhesion to post-capillary venules.  Under conditions of inflammation, rolling becomes 
slower, leading to firm adhesion between PMN and the capillary wall.  Several studies 
demonstrated (106,126) clear shedding of membrane bound L-selectin after PMN 
activation with different agents such as PMN, C5a, LTB4, IL-1, LPS and GM-CSF.  In 
contrast, in our study, treatment of PMN with LPS did not affect expression of L-selectin 
when compared to resting PMN.  A possible explanation for the lack of additional 
shedding of L-selectin from PMN after LPS stimulation could be that the PMN were 
already activated by the high concentration of cytokines in plasma during pregnancy (101, 
102).  However, our study did show that increasing concentration of PMN in the presence 
of LPS decreased L-selectin expression, probably due to proteolysis at the cell membrane 
level (101). 
LPS enhanced CD11b/CD18 expression (126).  The CD11b/CD18 integrin is a 
critical mediator for PMN surface adherence and also communicates signaling events 
evoked by various cytokines (85).  CD11b/CD18 integrins on PMN bind to 
myeloperoxidase released from PMN azurophilic granules, leading to induction of 
intracellular signaling cascades (115).  Our experiment showed that CD18 was up-
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regulated in a LPS dose-dependent manner.  TLR4 signaling by LPS activates synthesis 
and up-regulation of CD11b and is essential for PMN adhesion and transmigration (233).   
In conclusion, sCD14 release from PMN stimulated with LPS results from the 
shedding of membrane CD14 and suppresses secretion of IL-8 by PMN.  The suppression 
of IL-8, a potent chemoattractant of PMN, may be important in controlling an excessive 
PMN response during inflammation. 
 
.
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Figure 15. Percentage of apoptotic PMN (5 x 106 PMN /mL) following 6 h of incubation 
with varying concentrations of LPS in the absence (A) or presence (B) of FBS. Values 
differ from unstimulated PMN (*P<0.05). Means ± SEM of five individual experiments. 
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Figure 16. Percentage of apoptotic PMN (5 x 106PMN /mL) following 20 h of incubation 
with varying concentrations of LPS in the absence (A) or presence (B) of FBS.  Means  ± 
SEM of five individual experiments. Values did not differ from unstimulated PMN 
(P>0.05) 
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Figure 17. LPS (100 Ng/mL) decreased percentage of PMN expressing mCD14 when 
compared to media control (A) and increased when stimulated with 1 µg/mL in the 
presence of FBS (B).  Means ± SEM of six individual experiments. Values differ from 
unstimulated PMN (**P<0.001). 
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Figure 18. Expression of CD14 mRNA in PMN in response to LPS in the presence or 
absence of FBS.  After 1 h, cells were collected and total RNA was extracted and 
subjected to quantitative real time PCR.  Means ± SEM of four individual experiments.  
Values did not differ from unstimulated PMN (P>0.05) 
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Figure 19. LPS treatment resulted in enhanced CD18 expression on PMN in either the 
presence or absence of 5% FBS.  Values differ from media only (*P<0.05, **P<0.001).  
Means  ± SEM of six individual experiments 
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Figure 20. Release of sCD14 from PMN in the absence (A) or presence of FBS (B) after 
20 h of incubation with different concentrations of LPS.  Supernatants were assayed for 
CD14 by ELISA.  In the absence of FBS, 100 µg/mL of LPS induced release of CD14 
from PMN (*P<0.05).  In the presence of FBS values did not differ from media only 
(P>0.05). Means ± SEM of least four individual experiments. 
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Figure 21. Concentration of sCD14 in supernatants after stimulation of PMN with 100 
µg/mL of LPS in the presence of in the presence (A) or absence (B) of FBS after 6,16, 20 
h of incubation. Values differ from stimulated PMN with LPS at 6 h (*P<0.05. 
**P<0.001).  Means ± SEM of three individual experiments. ND = Non dectable. 
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Figure 22. Release of IL-8 from PMN in the absence (A) or presence of FBS (B) after 20 
h of incubation with different concentrations of LPS.  Supernatants were assayed for IL-8 
by ELISA.  In the absence of FBS, 1 and 10 µg/mL of LPS induced release of IL-8 from 
PMN.  In the presence of FBS, all concentrations of LPS induced release of IL-8.  Values 
differ from media only (*P<0.05, ** P<0.001).  Means ± SEM of five individual 
experiments. ND = Non dectable. 
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Figure 23. Effect of PMN concentration on release of sCD14 (A) and secretion of IL-8 
(B) in response to 10 µg/mL of LPS in the absence of FBS.  Values differ from 1 x 107
PMN/mL (* P<0.05, **P<0.001).  Means ± SEM of four individual experiments. 
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Figure 24. Effect of PMN concentration on release of sCD14 (A) and and secretion of 
IL-8 (B) in response to 0.1 µg/mL LPS in the absence of FBS. Values differ from 1 x 107
PMN/mL (* P<0.05, **P<0.001).  Means  ± SEM of four individual experiments. 
 
*
*
*
91
A
B
C
.
10 5 2.5 1
0
100
200
300
400
Cell density of PMN (107/mL)
PG
E 2
(p
g/m
L)
0 1 10 100
0
50
100
150
Concentration of LPS (µg/mL)
PG
E 2
(p
g/m
l)
0 1 10 100
0
100
200
300
C o n cen tr a t io n  o f L P S  (µ g /m L )
PG
E 2
(p
g/m
l)
*
*
** ** **
*
92
Figure 25. Release of PGE2 from PMN (5 x 106 PMN/mL) in the absence (A) or presence 
(B) of FBS after 20 h of incubation with different concentrations of LPS in RPMI media.  
Effect of cell density on PGE2 secretion in response to 0.1 µg/mL of  LPS in the absence 
of FBS (C). Cell supernatants were assayed for PGE2. Values differ from media only (* 
P<0.05, ** P<0.001). Means  ± SEM of four individual experiments. 
 
93
 
A
Figure 26. The expression of L-selectin on PMN (5 x 106 PMN/mL) in the absence and 
presence of FBS after 20 h of incubation with different concentrations of LPS (A).  Effect 
of cell density on L-selectin expression in response to 0.1 µg/mL of LPS in the absence 
of FBS (B). Values differ from media only (A), and from 0.5 x 107/mL PMN (B) 
(*P<0.05, **P<0.001). Means ± SEM of five individual experiments.  
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Chapter Five: Cytokine Production by Bovine Neutrophils Stimulated 
with LPS 
 
ABSTRACT
After intramammary infection, polymorphonuclear neutrophil leukocytes (PMN) 
are the first cells recruited into the mammary gland.  Rapid recruitment and bacterial 
phagocytosis and killing by PMN are the most effective defenses against establishment of 
bacterial infection.   In addition to their phagocytic and bactericidal properties, PMN may 
play a key supportive role, through secretion of cytokines during the innate immune 
response.   We sought to determine whether bovine PMN produce cytokines in response 
to stimulation by LPS.  To investigate the effects of LPS on the expression of cytokines 
secreted by bovine PMN, we measured the expression of TNF-?, IL-1B, IL-12, and IFN-C
by ELISA after stimulation with different concentrations of LPS, and secretion of IL-8 
and IFN-C after stimulation with LPS co-incubated with TNF-?, IL-1B and IL-12    
Bovine PMN were shown to secrete TNF-?, IL-1B, IL-12, IL-8 and INF-C in the response 
to LPS.  The secretion of TNF-?, IL-1B, and INF-C increased in a dose-dependent 
manner, whereas IL-12 decreased with increasing concentrations of LPS.  Co-incubation 
of LPS with either TNF-? or IL-1B increased secretion of IL-8 when compared to LPS 
alone, and no effect was observed for IL-12.  It was concluded that LPS stimulation can 
up-regulate the secretion of cytokines by bovine PMN, and that co-incubation of LPS 
with TNF-? or IL-1B had an additive effect on the secretion of IL-8.  These data show 
that bovine PMN, in addition to their phagocytic and bactericidal properties, may play a 
supportive role in the innate immune response to infection by Gram-negative bacteria.  
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 INTRODUCTION
During intramammary infection PMN, the first cells recruited are attracted by 
chemotactic agents such as IL-8, IL-1 and leukotrience B4 released from activated 
endothelium and macrophages (28). In mammary quarters free from bacterial infection, 
macrophages are predominant cell type (35-79%), followed by PMN (3-26%), 
lymphocytes (10-24%) and epithelial cells (2-15%).  During intramammary infection, the 
percentage of PMN increases and can approach 100% (116, 142, 150).  Migration of 
PMN into tissue provides the first immunological line of defense against bacterial 
infection. 
 PMN are short-lived white blood cells that play a vital role in the inflammatory 
response and are considered to be differentiated effector cells capable of phagocytosis 
and intracellular killing.  IL-1B, IL-8, and TNF-?, contribute to the establishment of 
inflammation by altering vascular permeability, promoting PMN recruitment to the site of 
infection, and inducing hepatic synthesis of acute phase proteins that facilitate 
complement activation and host detection of bacterial cell well products (56, 67).  IL-12, 
which is produced by phagocytic cells and B-lymphocytes in response to LPS, plays a 
key role in the initiation of both innate and antibody-specific pro-inflammatory immunity 
(213).  IL-12 also enhances the cytotoxic activity of natural killer (NK) cells (2, 165).  
IFN-C plays a central role in controlling the host’s response to bacterial and viral infection 
(46), because it can both enhance and suppress chemokine secretion in response to pro-
inflammatory cytokines such as IL-1B and TNF-?, modulate chemokine receptor 
expression, and affect diapedsis of PMN into tissue (206). 
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PMN and mononuclear cells play important roles in the host defense to Gram-
negative infection.  Most studies have focused on the immunomodulation change of 
bovine mononuclear cells, and only a few have been conducted on immunomodulation 
changes of bovine PMN.  Several cytokines have been proposed to be involved in 
mastitis, including IL-1, IL-8, TNF-? and IL-12 (170, 193) and are responsible for 
modulating the physiological functions of PMN (71, 201).  The purpose of this study was 
to determine the expression of cytokines by bovine PMN in response to LPS.   
MATERIAL AND METHODS
PMN culture and activation 
 PMN were adjusted to 5 x 106/mL in RPMI containing 5% FBS, and added to 96-
well tissue culture plates (200 µL/well), and incubated at 37VC in a 5% CO2 incubator for 
18 h.  To study the release of INF-C, PMN were cultured with or without 5% FBS in 
either media alone (control), LPS (0.1 µg/mL), human IL-12 (Serotec, UK), LPS plus IL-
12 or with different concentration of LPS (1, 10, and100 µg/mL).  To study the release of 
IL-8, PMN were cultured with either media alone, human TNF-? (10 ng/mL) (Endogen),  
bovine IL-1B (10 ng/mL) (Endogen), 0.1 Ng/mL of LPS plus either human TNF-? (10 
ng/mL) (Endogen), bovine IL-1B (10 ng/mL) (Endogen).  After 18 h, cells and cell 
supernatants were separated by centrifugation (9,300 x g, 5 min, at 4oC) and cell 
supernatants were harvested.  For the time course experiments, PMN were cultured with 
0.1 µg/mL LPS and supernatants were collected at 0, 3, 6, 9, and 18 h after centrifugation 
(9,300 x g, 5 min, at 4VC) for determination of INF-C, IL-1B, IL-12, and TNF-?.
Supernatants were stored at -20°C for further processing.  
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Quantitiation of IL-8 and IFN-H
IL-8 and IFN-C were determined in undiluted PMN supernatants with a 
commercially available human IL-8 ELISA kit (R&D Systems).  Bovine IFN-C was 
assayed with a commercially available EASIA kit (Biosource, Nivelles, Beligium).  OD 
at 450 nm and a correction wavelength 550 nm were measured on a microplate reader.   
 
Quantitiation of IL-12 
 Flat bottom 96-well plates were coated overnight at 4VC with 4 µg/mL of mouse 
anti-human IL-12 (Serotec) antibody diluted in 0.05 M sodium carbonate, pH 9.6.  The 
plates were washed three times with 0.05% Tween-20 diluted in 50 mM TBS, pH 8.0, 
and blocked with 2% fish skin gelatin (Sigma) for 1 h at room temperature.  The plates 
were washed and 100 µL of sample was added to the anti-IL-12-coated plates.  Following 
a 2 h incubation at room temperature, the plates were washed, and 100 µL of biotin-
conjugated mouse anti-bovine IL-12 (Serotec) antibody diluted to 1 µg/mL was added to 
each well.  The plates were incubated for 1 h at room temperature and washed.  HRP-
conjugated strepavidin (Sigma) was diluted 1:500 in TBS wash buffer containing 0.2% 
gelatin, and 100 µL of this solution was added to each well.  The plates were incubated 
for 1 h at room temperature and washed.  TMB substrate solution (Sigma) was added to 
each well.  The reaction was stopped by the addition of 100 µL of 2M H2SO4 ,and the 
absorbance was read at 450 nm on a microplate reader. 
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Quantitiation of IL-1I and TNF-9
Flat bottom 96-well plates were coated overnight at 4VC with 5 µg/mL of mouse 
anti-bovine IL-1B (Serotec) antibody or with100 µL of anti-mouse TNF-? mAb (154) 
diluted 1:2000 in 0.05 M sodium carbonate, pH 9.6.  The plates were washed three times 
with 0.05% Tween 20 diluted in 50 mM TBS, pH 8.0, and blocked with 2% fish skin 
gelatin (Sigma) for 1 h at room temperature.  The plates were washed, and 100 µL of 
sample was added to the anti-IL-1B or anti-TNF-?-coated plates.  Following a 2 h 
incubation at room temperature, the plates were washed, and either 100 µL of rabbit 
polyclonal anti-bovine IL-1B (Serotec) antibody diluted to 1: 500 or 100 µL of rabbit 
polyclonal anti-bovine TNF-? antibody diluted 1:20,000 were added.  The plates were 
incubated for 1 h at room temperature and washed.  HRP-conjugated anti-rabbit IgG 
(Sigma) was diluted 1: 5000 in TBS wash buffer containing 0.2% gelatin, and 100 µL of 
this solution was added to each well.  The plates were incubated for 30 min at room 
temperature and washed.  TMB substrate solution (Sigma) was added to each well.  The 
reaction was stopped by the addition of 100 µL of 2M H2SO4 and the absorbance was 
read at 450 nm on a microplate reader. 
 
Statistical methods 
The unpaired or paired t-test (Prism version 4.0 for Windows; GraphPad Software 
Inc.) was used for the statistical analysis.  P values below 0.05% were considered 
significant.
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RESULTS
Secretion of IL-8 by PMN 
 
Neither TNF-? or IL-1B elicited an enhanced (P > 0.05) release of IL-8 from 
PMN when compared to media alone, although a slightly enhanced IL-8 release in the 
presence of TNF-?, and IL-B was detected (5.68 ± 2.5, 14.3 ± 7.4 pg/mL) (Figure 27).  In 
the presence of 0.1 µg/mL LPS, PMN exhibited enhanced (P < 0.05) IL-8 release, 
averaging 91.4 ± 38 pg/mL.  Adding LPS together with either TNF-? or IL-1B further 
increased (P < 0.05) IL-8 release (202 ± 80 and 116.7± 46 pg/mL) (Figure 27). 
IL-12 in the absence of 5% FBS enhanced (P < 0.05) INF-C release from PMN 
(780.7 ± 87.8 pg/mL), but LPS or LPS plus IL-12 produced no increase when compared 
to control cells in the absence of FBS (Table III).  No changes were observed in the 
presence of FBS. 
 
Effect of different concentrations of LPS on INF-H secretion by PMN 
 Unstimulated control PMN secreted IFN-C (71 ± 46 pg/mL) after 18 h of 
incubation, similar to IFN-C concentrations observed when incubated with either 1 or 10 
µg/mL of LPS (Figure 28A).  Secretion of IFN-C increased (P < 0.05) (162  ± 48 pg/mL) 
in the presence of 100 µg/mL of LPS.  INF-C was secreted immediately after stimulation 
with 0.1 µg/mL of LPS, and then decreased (P < 0.05) with increased time of incubation, 
except at 9 h of incubation (Figure 28B). 
100
Effect of different concentrations of LPS on IL-1I secretion by PMN 
 IL-1B increased (P < 0.05) with the different concentrations (1, 10 and 100 
µg/mL) of LPS when compared to media control (Figure 29A).  In the time course 
experiment, IL-1B increased (P < 0.05) at 9 h, and maximal secretion occurred at 18 h 
after stimulation with 0.1 µg/mL of LPS (Figure 29B). 
 
Effect of different concentrations of LPS on IL-12 secretion by PMN 
Secretion of IL-12 increased (P < 0.05) after incubation with either 1 or 10 µg/mL 
of LPS when compared to media control (Figure 30A).  The increase observed with 100 
Ng/mL of LPS was not different (P > 0.05) from media control.  The length of incubation 
time on release of IL-12 after stimulation with 0.1 µg/mL of LPS had no effect on IL-12 
secretion until after 18 h (P < 0.05) (Figure 30B). 
 
Effect of different concentrations of LPS on TNF-9 secretion by PMN 
 Unstimulated PMN immediately secreted TNF-? (0.75 ± 0.05 ng/mL) (Figure 
31A).  Secretion of TNF-? was further elevated (P < 0.05) in culture media containing 10 
and 100 µg/mL of LPS.  The increase observed at 1 µg/mL of LPS was not different (P < 
0.05) from media control.  The secretion of TNF-? was already elevated (1.5 ng/mL) at 
time 0 and further increased (P < 0.05) at 6 h after stimulation with 0.1 µg/mL of LPS 
(Figure 31B).  The highest concentration of TNF-? occurred at 18 h.  
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DISCUSSION
The results of this study demonstrate that circulating bovine PMN responds to 
LPS stimulation by secreting TNF-?, IL-1B, IFN-C, IL-8 and IL-12, and contributes to the 
innate immune response in dairy cows.   
 TNF-? has been reported to stimulate IL-8 release by human PMN (212), whereas 
in the present study TNF-? alone had no effect on IL-8 secretion by bovine PMN (Figure 
27).  TNF-? increases phagocytosis, degranulation and oxdative burst activity of bovine 
PMN and expression of endothelial cell adhesion molecules by promoting PMN 
adherence to vascular endothelium.  One study reported that bovine periperal PMN were 
capable of releasing TNF-? following stimulation with bacterial LPS (149). 
 The results of the present study showed that secretion of TNF-?, IL-1B, IFN-C, IL-
8 and IL-12 by bovine PMN was induced by LPS. IL-1B can stimulate T-helper cells and 
B-cells to synthesize immunoglobulin, and also promotes the adhesion of PMN, 
monocytes, T-cells, and B-cells to endothelium by enhancing the expression of adhesion 
molecules such as the intracellular adhesion molecule, endothelial leukocyte adhesion 
molecule and the proliferation and activation of NK cells as well (116).  Secretion of 
TNF-?, IL-1B and IL-12 peaked at 18 h (Figure 28, Figure 29, Figure 30). In contrast, 
release of IL-12 showed a dose-dependent decrease (Figure 30 A). Several studies (3, 
170, 171) reported that in the bovine mammary gland, mRNAs for IL-1 B, IL-6, TNF-?,
IL-8 and IL-12 were detected in PMN from glands experimentally challenged with S. 
aureus ?-toxin and S. aureus.
IL-12 was the most efficient stimulus after18 h of culture in up-regulating INF-C
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production (Table III).  IL-12 is chemotactic for human PMN, and also activates IL-8 and 
TNF-? synthesis (1).  The biological activities of IL-12 include enhancement of cytotoxic 
T cell and lymphokine-activated killer cell generation and activation, increased natural 
killer cell cytotoxicity, induction of activated T-cell and NK-cell proliferation, induction 
of INF-C production by NK cells and T cells, and inhibition of IgE synthesis by IL-4 
stimulated lymphocytes via INF-C dependent and independent mechanisms (76, 104).   
The ability of PMN to produce INF-C points to a new role for bovine PMN during 
the innate immune response.  Human PMN contain a small store of INF-C and this store 
is rapidly secreted upon stimulation by degranulating agents such as formyl peptides. 
After a few hours of stimulation, PMN synthesizes INF-C (64).  This is consistent with 
our study that bovine PMN secrete INF-C immediately after LPS stimulation.   
LBP is known as a lipid transfer protein that presents LPS to CD14 receptors (82).  
TLR4, TLR2, and CD14 are important for mediating immune cell responses to LPS (161, 
227).  PMN express low levels of TLR4, and moderate levels of TLR2 and CD14 (109).  
Several studies (91, 134, 159) have described CD14-independent LPS effects.  Activation 
of TLR4-dependent signal transduction pathways appears to require participation of 
CD14 (39,113).  TLR2 is CD14-independent LPS receptors and does not require CD14 
for initiation of intracellular pathways, and the role of TLR2 in this response remains 
unclear (208).  Cell-surface CD11b/CD18 is a receptor for LPS.  When LPS activation is 
mediated by CD11b/CD18, serum is not required for transmembrane signal transduction 
(95). 
 Several studies showed that human PMN produced TNF-?, IL-12 and IL-8, after 
stimulation with microbial products such as bacterial LPS, Toxoplasma gondii and 
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Candida albicans (30, 33, 34).  While PMN normally undergo rapid apoptosis during 
culture, several inflammatory cytokine (e,g, IL-1B, TNF-?, IL-6, G-CSF, GM-CSF) 
prolong their life span, suggesting that PMN may be longer-lived during infections than 
previously believed (13, 42).  
To date, no one has demonstrated cytokine expression in bovine circulating PMN in 
response to LPS.  The findings in this study that PMN are capable of producing several 
major inflammatory cytokines in response to LPS, suggests that PMN may be important 
in directing early cell trafficking and cytokine-producing activities during infection by 
microbial pathogens. 
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Table III. INF-C secretion by bovine PMN after incubation (18 h, 37VC) with LPS (0.1 
µg/mL) and human IL-12 (5 ng/mL) in the presence and absence of 5% FBS (n=5). 
*Significantly different (P < 0.05) from media control. 
 
Stimuli                INF-H (pg/ml) without FBS             INF-H (pg/ml) with FBS     
None                     548.3   ± 49.7                                        425     ± 83.4 
LPS                       487.1   ± 313.4                                      291.4   ± 91.9 
IL-12                     780.7   ± 87.8  (*)                                 450.4   ± 58 
LPS+IL-12            597.2   ± 85                                           425.9   ± 83.4 
 _____________________________________________________________________
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Figure 27. The effect of different stimuli on IL-8 release from bovine PMN (4 x 106
PMN/mL).   PMN were incubated for 18 h at 37VC with RPMI, hTNF-? (10 ng/mL), bIL-
1B (10 ng/mL), LPS (0.1 ng/mL), hTNF-? (10 ng/mL) + LPS (0.1 µg/mL), bIL-1B (10 
ng/mL)+ LPS (0.1 µg/mL).  Results are expressed as means with S.E.M. (n=5).   
*Significantly different (P<0.05) from media control. 
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Figure 28. Concentration of IFN-C in supernatants after incubation (18 h, 37VC) of PMN 
with LPS.  A) PMN were plated at 5 x 105cells/well in 96 well plates and were stimulated 
with different concentrations of LPS (n=10). *Significantly different (P<0.05) from 
media control.  B) Time course of IFN-C production after stimulation with 0.1 µg of LPS 
(n=3).  Results are expressed as means with S.E.M.  *Significantly different (P<0.05) 
from PMN supernatant collected immediately after LPS stimulation. 
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Figure 29. Concentration of IL-1B in supernatants after incubation (18 h, 37VC) of PMN 
with LPS in the absence of presence of 5% FBS. A) PMN were plated at 5 x 105cells/ 
well in 96 well plates and were stimulated with different concentrations of LPS (n=5).  
*Significantly different (P<0.05) from media control. B) Time course of IL-1B
production after stimulation of 0.1 µg LPS (n=3).  Significantly different (P<0.05) from 
PMN supernatant collected immediately after LPS stimulation. Results are expressed as 
means with S.E.M.  
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Figure 30. Concentration of IL-12 in supernatants after incubation (18 h, 37VC) of PMN 
with LPS.   A) PMN were plated at 5 x 105cells/well in 96 well plates and were 
stimulated with different concentrations of LPS (n=5).  *Significantly different (P<0.05) 
from media control.  B) Time course of IL-12 production after stimulation with 0.1 µg 
LPS (n=3). *Significantly different (P<0.05) from PMN supernatant collected 
immediately after LPS stimulation.  Results are expressed as means with S.E.M. 
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Figure 31.  Concentration of TNF-? in supernatants after incubation (18 h, 37VC) of 
PMN with LPS.   A) PMN were plated at 5 x 105cells/ well in 96 well plates and were 
stimulated with different concentrations of LPS (n=5). *Significantly different (P < 0.05) 
from media control B) Time course of TNF-? production after stimulation with 0.1 µg 
LPS (n=3). *Significantly different (P<0.05) from PMN supernatant collected 
immediately after LPS stimulation.  Results are expressed as means with S.E.M.   
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Chapter Seven: General Discussion 
Mastitis is defined as an inflammatory reaction within the mammary gland caused 
by invading bacteria through the teat canal located at the teat end of the mammary gland.  
Mastitis results in decreased milk production, increased veterinary costs, and culling and 
death of animals.  Sepsis is associated with excessive activation of a number of host 
mediator systems, including cytokines, leukocytes, and the vascular endothelium, each of 
which can contribute to the development of tissue injury (251). 
Binding to CD14 is considered to be a common pathway for induction of the 
innate immune response to a variety of microbial pathogens.  Gram-negative bacteria can 
bind to m- and sCD14 in the presence of serum, which indicates that LPS incorporated 
into the membrane of Gram-negative bacteria can interact with CD14 (29, 220).  CD14 
on human monocytes and macrophages exists as two soluble forms in normal plasma 
(59).  This is in agreement with our study (Chapter 2) that sCD14 in bovine milk and 
plasma exists as two soluble forms of 53 and 58 kDa.  Varying degrees of glycosylation 
contributes to the heterogeneity of the sCD14 molecule (202).  Gram-negative or Gram-
positive bacteria are powerful stimuli of cytokine production, which causes sepsis (145).  
In our study (Chapter 2), LPS-induced release of TNF-? by isolated monocytes was 
reduced by anti-rbosCD14 mAb.  The inhibitory effect of anti-rbosCD14 mAb on the 
secretion of TNF-? by LPS-stimulated monocytes can be due to impaired binding of 
these stimuli to CD14 or decreased activation of monocytes via CD14.  Anti-CD14 mAb 
administered after injection of LPS, protected rabbits from renal and pulmonary injury, 
and prevented hypotension (187).  Blocking of the CD14 receptor by using mAbs will 
inhibit the inflammatory response to LPS and may be beneficial in severe sepsis. 
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 A number of biopharmaceuticals, including vaccines and therapeutic proteins, 
have been expressed in plants (132, 207), the primary motivation being reduced cost   
therapeutics in a plant system.  The protective effect of rbosCD14 produced in a 
baculovirus of producing expression system was previously demonstrated in a mouse 
model and in lactating cows (117, 118, 119).  In the present study (Chapter 3), the plant-
derived rbosCD14 was shown to be a biologically active protein, possessing 
characteristics similar to rbosCD14: LPS induced apoptosis, caspase activity, and IL-8 
production in bovine endothelial cells.  PrbosCD14 sensitized the mammary gland to 
LPS, increasing the number of milk SCC, and showed a protective effect when tested in a 
bovine mastitis model.  Taking into account the previously reported therapeutic effect of 
sCD14 against pathogenesis of coliform mastitis, expression of CD14 in plants and 
purification of plant-produced protein was aimed at reducing the cost of production of 
recombinant CD14 for preventive administration to lactating dairy cows. 
 PMN are important cells in the first line of defense against bacterial invasion of 
the bovine mammary gland.  The increase in sCD14 was suggested to be associated with 
the accumulation of PMN at inflammatory sites (37, 117). Circulating PMN exhibit low 
mCD14 expression due to its shedding from the cell surfaces of stimulated PMN from 
patients with acute respiratory distress syndrome (157).  These studies are in agreement 
with our study (Chapter 4) that LPS causes a decrease in the percentage of PMN 
expressing mCD14, resulting in an increase of sCD14 at the highest concentration of LPS 
in the absence of FBS.  sCD14 found in human serum has been attributed to the shedding 
of mCD14 from monocytes, macrophage, and PMN (59).  In our study (Chapter 4), the 
release of sCD14 from PMN caused down-regulation of IL-8 secretion from PMN in 
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response to LPS.  Further, the increase of sCD14 with increasing cell densities of PMN in 
response to LPS was also parallel with the decrease of IL-8.  It was reported that 
production of IL-8 was inhibited via CD14 cleavage by human leukocytes elastase, which 
might be another mechanism for the down-regulatory cascade of inflammation (146).  
Burkholderia cepacia induced IL-8 synthesis in human lung epithelial cells in a CD14 
and mitogen activated protein kinase dependent manner (169). 
 Several studies showed that human PMN produced TNF-?, IL-12 and IL-8, after 
stimulation with microbial products such as bacterial LPS, Toxoplasma gondii and 
Candida albicans (30, 33, 34).  In our study (Chapter 5), we demonstratead for the first 
time that, bovine PMN produced TNF-?, IL-B, IL-8, INF-C, and IL-12 in response to 
LPS.  In addition, IL-12 was the most efficient stimulus in up-regulating INF-C
production.  While PMN normally undergo rapid apoptosis during culture, several 
inflammatory cytokines (e.g, TNF-?, IL-1B, IL-8, INF-C, IL-12, G-CSF, and GM-CSF) 
prolong their life span, suggesting that PMN may be longer-lived during infections than 
previously believed (23, 42).   
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Chapter Six: Conclusions: 
 Conclusions from the chapter ‘The Production and Characterization of Anti-
bovineCD14 Monoclonal Antibodies’ are: 
1. Anti-rbosCD14 mAb recognized a 53 and 58 kDa sCD14 in milk and blood, 
and a 47 kDa mCD14 in macrophages and monocytes by Western blotting analysis.   
2. The anti-rbosCD14 mAb bound with mCD14 on the surface of mouse 
macrophages suggest that bovine CD14 has cross-reacted with mouse macrophages but 
not with macrophage from horse and pig. 
3. An increase of sCD14 in milk was detected by ELISA between 8 to 48 h after 
intramammary injection of LPS.  
4. Anti-rbosCD14 to mCD14 on macrophage, reduced secretion of TNF- ? from 
macrophage after stimulation with LPS, and will be useful in studying the 
interrelationship between CD14 and LPS during mastitis.  
 Conclusions from the chapter ‘Expression of a Functional Bovine CD14 Receptor 
in Plants’ are: 
1. sCD14 was incorporated into potato virus x (PVX). Bovine sCD14 was 
expressed in plants and purified.  sCD14 was identified on Western blotting analysis and 
ELISA.  It was designated as plant-derived sCD14 (prbosCD14).  
 2. Plant-derived sCD14 caused apoptosis, IL-8 producton and caspase acticity in 
cultured endothelial cells. 
 3. After intramammary injection with 0.3 µg of LPS plus prbosCD14, milk SCC  
increased, and numbers of E. coli and clinical symptoms were reduced.   
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Conclusions from the chapter ‘Shedding of sCD14 by Bovine PMN Following 
Activation with LPS Results in Down-Regulation of IL-8’ are: 
1. CD14 comes the shedding of mCD14 on the surface of PMN. 
2.  Release of sCD14 by PMN reduced the secretion of IL-8. The release of 
sCD14 from PMN caused down-regulation of IL-8 secretion from PMN (Figure 32).     
 
Figure 32. Schematic drawing of the objectives of this thesis. Binding of LPS by 
LBP/mCD14 on PMN leads to the shedding of sCD14 by losing GPI linker from mCD14, 
and then the sCD14 results in the down-regulation of IL-8. 
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Conclusions from the chapter ‘Cytokine Production by Bovine Neutrophil 
Stimulated with LPS’ are: 
Adding LPS together with either TNF-? or IL-1 B increased IL-8 release 
compared to LPS only.  IL-12 in the absence of FBS enhanced INF-C release from PMN.   
 
116
Literature Cited 
 
1. Al-Mohanna F, Saleh S, Parhar RS. 2002. IL-12 dependent nuclear factor-kappa B  
 activation leads to de novo synthesis and release of IL-8 and TNF-? in    
 human neutrophils. J Leukoc Biol. 72:995-1002. 
 
2. Allavena P, Paganin C, Zhou D, Sozzani S, Mantovani A. 1994. Interleukin-12 is  
chemotactic for NK cells and stimulates their interaction with vascular  
 endothelium. Blood. 84:2261-2268. 
 
3. Alluwaimi AM, Leutenegger CM, Farver TB, Rossitto PV, Smith WL and Cullor  
JS. 2003. The cytokine markers in staphylococcus aureus mastitis of   
bovine mammary gland.  J Vet Med. 50:105-111. 
 
4. Anderson KL, Smith AR, Gustafsson BK, Spahr SL, and Whitmore HL. 1982.  
Diagnosis and treatment of acute mastitis in a large dairy herd. J Am Vet 
Med Assoc. 181:690-693. 
 
5. Anri A. 1989. Detection of endotoxin in affected milk from cows with coliform  
 mastitis. Nippon Juigaku Zasshi. 51:847-848. 
 
6. Antal-Szalmas P, Van Strijp JAG, Weersink AJL, Verhoef  J, Van Kessel KPM.  
1997.Quantitation of surface CD14 on human monocytes and neutrophils.  
Leukoc J Leukoc Biol. 61:721-728. 
 
7. Ariti M, Zhou J, Dorio R, Rong G, Goyert S, Kim K. 1993. Endotoxin-mediated 
endothelial cell injury and activation: role of soluble CD14. Infect.
Immun. 61:3149-3156. 
 
8. Baggiolini M. 1998. Chemokines and leukocytes traffic. Nature. 392:565-568. 
 
9. Baggiolini M, Moser B, Clark-Lewis I. 1994. Interleukin-8 and related chemotactic   
cytokines. The Giles Filley Lecture. Chest. 105:95S-98S. 
 
10. Bainton DF, Ullyot JL, Farquhar MG. 1971.The development of neutrophilic  
polymorphonuclear leukocytes in human bone marrow. Exp Med.
1:907-934. 
 
11. Banks KL, Michaels FH. 1985. Stimulaton and killing of bovine mononuclear  
leukocytes by bacterial lipopolysaccharide (endotoxin). Am Vet Res.
4:1568-1572. 
 
12. Bannerman DD, Sathyamoorthy M, Goldblum SE. 1998. Bacterial  
 lipopolysaccharide distrupts endothelial monolayer integrity and  
survival signaling events through caspase cleavage of adherens  junction 
proteins. J Biol Chem. 25:35371-35380. 
117
 
13. Bannerman DD, Tupper JC, Kelly JD, Winn RK, Harlan JM. 2002. The Fas- 
associated death domain protein suppresses activation of NF-kappa B by 
LPS and IL-1 beta. J Clin Invest. 109:419-425. 
 
14. Bannerman DD, Paape MJ, Hare WR, and Sohn EJ. 2003. Increased levels of  
LPS-binding protein in bovine blood and milk following bacterial  
lipopolysaccharide challenge. J Dairy Sci. 86:3128-3137. 
 
15. Bannerman DD, Paape MJ, Goff JP, Kimura K, Lippolis JD, Hope JC. 2004. 
Innate immune response to intramammary infection with Serratia 
marcescens and Streptococcus uberis. Vet Res. 35:681-700. 
 
16. Bannerman DD, Paape MJ, Lee JW, Zhao X, Hope JC, Rainard P. 2004.  
Escherichia coli and Staphylococcus aureus elicit differential innate 
immune responses following intramammary infection. Clin Diagn Lab 
Immunol. 11:463-472. 
 
17. Barber MR, Yang TJ. 1998. Chemotactic activitics in nonmastitic and mastitic  
mammary secretions: presence of interleukins-8 in mastitic but not 
nonmastitic secretions. Clin Diagn Lab Immunol. 5:82-86. 
 
18. Bazil V, Horeji V, Baudays M, Kristofova H, Strominger J, Kostka W, Hilgert I.  
1986.Biochemical characterization of a soluble form of the 53-kDa 
monocytes surface antigen. Eur J Immunol. 16:1583-1589. 
 
19. Bazzoni F, Giovedi S, Kiefer MC, Cassatella MA. 1999. Analysis of the Bak  
protein expression in human polymorphonuclear neutrophils. Int J Clin 
Lab Res. 29:41-45. 
 
20. Berczi I. 1998. Neurohormonal host defense in endotoxin shock. Ann N Y Acad  
 Sci. 840:787-802. 
 
21. Blondin C, Le Dur A, Cholley B, Caroff M, Haeffner-Cavaillon N. 1997.  
 Lipopolysaccharide complexed with soluble CD14 binds to normal  
 human monocytes. Eur J Immunol. 27:3303-3309. 
 
22. Boudjellab N, Chan-Tang HS, Zhao X. 2000. Bovine interleukin-1 expression by  
cultured mammary epithelial cells (MAC-T) and its involvement in the     
release of MAC-T derived interleukin-8. Comp Biochem Physiol A Mol 
Integr Physiol. 27:191-199. 
 
23. Brach MA, deVos S, Gruss HJ, Herrmann F. 1992. Prolongation of survival of  
human polymorphonuclear neutrophils by granulocyte-macrophage   
colony-stimulating factor is caused by inhibition of programmed cell 
death.  Blood. 80:2920-2904. 
118
 
24. Bramley AJ. 1976.Variations in the susceptibility of lactating and non-lactating  
bovine udders to infection when infused with Escherichia coli. Dairy Res.
43:205-211. 
 
25. Bufler P, Stiegler G, Shuchmann M, Hess S, Kruger C, Stelter F, Eckerskorn C,  
Schutt C, and Engelmann H. 1995. Soluble lipopolysaccharide receptor  
(CD14) is released via two different mechanisms form human monocytes 
and CD14 transfectants. Eur J Immunol. 25:604-610. 
 
26. Burvenich C, Paape MJ, Hill AW, Guidry AJ, Miller RH, Heyneman R, Kremer  
WD, Brand A. 1994. Role of the neutrophil leucocyte in the local and 
systemic reactions during experimentally induced E. coli mastitis in cows 
immediately after calving. Vet Q. 16:45-50. 
 
27. Burvenich C, Van Merris CJ, Mehrzad J, Diez-Fraile A, and Duchateau L. 2003.  
Severity of E.col mastitis is mainly determined by cow factors. Vet Res.
34:521-564. 
 
28. Butcher C. 1991. Leukocyte-endothelial cell recognition: three (or more) steps to  
specificity and diversity. Cell. 67:1033-1036. 
 
29. Bone RC. 1993. Gram-negative sepsis: a dilemma of modern medicine. Clin  
Microbiol Rev. 6:57-68. 
 
30. Cacalno G, Lee K, Kikly A, Ryan, Pitts-Meek S, Hultgren B, Wood W, Moore 
 M. 1994. Neutrophil and B cell expansion in mice that lack the murine 
 IL-8 receptor homolog. Science. 29:590-591. 
 
31. Carroll EJ, Schalm OW, Lasmanis J. 1964. Experimental coliform (Aerobacter  
aerogenes) mastitis: Characteristics of the endotoxin and its role in  
pathogenesis. Am J Vet Res. 25:720-726. 
 
32. Carlson GP, Kaneko J. 1973. Isolation of leukocytes from bovine peripheral 
blood. Proc Soc Exp Biol Med. 142:853-856. 
 
33. Casstella MA. 1995. The production of cytokines by polymorphonuclear  
neutrophils. Immunol Today. 16:21-26. 
 
34. Cassatella MA, Meda L, Gasperini S, Andrea AD, Ma X, Trinchieri G.  
1995. Interleukin-12 production by human polymorphonuclear   
leukocytes. Eur J Immunol. 25:1-5. 
 
35. Cassatella MA.1996. Cytokines produced by polymorphonuclear neutrophils: 
molecular and biological  aspects. R.G. Landes Company, Austin,    
Texas, USA. 
119
 
36. Cassatella MA, Gasperini S, and Russo MP. 1997. Cytokine expression and  
release by neturophils. Ann NYAcad Sci. 832:233-242. 
 
37. Cauwels A, Frei K, Sansano S, Fearns C, Ulevitch R, Zimmerli W, Landmann R. 
1999. The origin and function of soluble CD14 in experimental bacterial 
meningitis. J Immunol. 162:4762-4772. 
 
38. Chapman S, Kavanagh T, Baulcombe D. 1992. Potato virus X as a vector for gene  
expression in plants. Plant J. 2:549-557. 
 
39. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. 1999. Toll-like  
receptor-4 mediates lipopolysaccharide-induced signal transduciton. J Biol 
Chem. 274:10689-10692.  
 
40. Craven N. 1986.Chemotactic factors for bovine neutrophils in relation to mastitis. 
Comp Immunol Microbiol Infect Dis. 9:29-36. 
 
41. Crozat K, Beutler B. 2004. TLR7: A new sensor of viral infection. Proc Natl  
Acad Sci USA. 101:6835-6836. 
 
42. Colotta F, Re F, Polentarutti N, Sozzani S, Mantovani A. 1992. Mondulation of  
granulocyte survival and programmed cell death by cytokines and  
bacterial products. Blood. 80:2012-2020. 
43. Daley M, Williams T, Coyle P, Furda G, Dougherty R, Hayes P. 1993 Prevention  
and treatment of Staphylococcus aureus infections with recombinant  
cytokines. Cytokine. 5:276-284. 
 
44. Daley MJ, Coyle PA, Williams TJ, Furda G, Dougherty R, Hayes PW. 1991. 
Staphylococcus aureus mastitis: pathogenesis and treatment with bovine 
interleukin-1 beta and interleukin-2. J Dairy Sci. 74:4413-4424. 
 
45. Dbravec DB, Spriggs DR, Mannick JA, Rodrick ML. 1990. Circulating human  
peripheral blood granulocytes synthesize and secrete tumor necrosis 
factor. Proc Natl Acad Sci USA. 87:6758-6761. 
 
46. Decker T, Stockinger S, Karaghiosoff M, Müller M, and Kovarik P. 2002. IFNs  
and STATs in innate immunity to microorganisms. J Clin Invest.
109:1271-1277. 
 
47. de Haas Y, Barkema HW, Veerkamp RF. 2002. The effect of pathogen-specific  
clinical mastitis on the lactation curve for somatic cell count. J Dairy Sci.
85:1314-1323. 
 
48. Dentener M, Bazil V, Von Asmuth E, Ceska M, Buurman W. 1993. Involvement  
120
of CD14 in lipopolysaccharide induced tumor necrosis factor-alpha, IL-6 
and IL-8 release by human monocytes and alveolar macrophage. J
Immunol. 150:2885-2891. 
 
49. Desidero JV, Campbell SG. 1980.  Bovine mammary gland macrophage:isolation, 
morphologic features, and cytophilic immunoglobulins. Am J Vet Res.
41:1595-1599. 
 
50. De Waal Malefyt R, Figdor CG, Huijbens R, Mohan-Peterson S, Bennett B,  
Culpepper L. 1993. Effect of IL-13 on phenotype, cytokines production, 
and cytotoxic function of human monocytes. J Immunol. 151:6370-6381. 
 
51. Debets J, Kamprmeijer HR, Van der Linden, W.A.Buurman, and C.J. Van der  
Linden. 1989. Plasma tumor necrosis factor and mortality in critically 
septic patients. Crit Care Med. 17:489-494. 
 
52. Dentener MA, Bazil V, Asmuth UV, Ceska M, Buuurman WA. 1993. Involvement 
of CD14 in lipopolysaccharide-induced tumor necrosis  factor-?, IL-6 and 
IL-8 release by human monocytes and alveolar macrophages. J Immunol.
150:2885-2891. 
 
53. Detmers PA, Zhou D, Powell D, Lichenstein H, Kelley M, Pironkova R. 1995.  
Endotoxin receptors (CD14) are found with CD16 (Fc gamma RIII) in an 
intracellular compartment of neutrophils that contains alkaline phosphatase.  
J Immunol. 155:2085-2095. 
 
54. Diez-Fraile A, Meyer E, Duchateau L, Burvenich C. 2004. Effect of pro- 
inflammatory and glucocorticoids on L-selectin expression in peripheral 
blood neutrophls from dairy cows in various stages of lactation. Am J Vet 
Res. 65:1421-1426. 
 
55. Didier JL, Moriarty AM. Talbott G, Winn RK, Martin TR, Ulevitch RJ. 1996. 
Antibodies against CD14 protect primates from endtotoxin-induced shock. 
J Clin Invest. 98:1533-1538. 
 
56. Dinarello CA. 1997. Proinflamatory and anti-inflammatory cytokines as mediators  
in the pathogenesis of septic shock. Chest. 112:321S-329. 
 
57. Donnet-Hughes, and Schiffrin EJ. 2000. Innate recognition of bacteria in human  
milk is mediated by a milk-derived highly expressed pattern recognition 
receptor, soluble CD14. J Exp Med. 191:1807-1812. 
 
58. Dosogne H, Meyer E, Sturk A, van Loon J, Massart-Leen AM, Burvenich C.  
2002. Effect of enrofloxacin treatment on plasma endotoxin during bovine 
Escherichia coli mastitis. Inflamm Res. 51:201-205. 
 
121
59. Duriex JJ, Vita N, Popescu O, Guette F, Calzada-Wack J, Munker R, Schmidt RE,  
Lupker J, Ferrara P, Ziegler HW, Labeta MO. 1994. The two soluble 
forms of the lipopolysaccharide receptor, CD14: Characterization and 
release by normal human monocytes. Eur J Immunol. 24:2006-2012. 
 
60. Eberhart RJ, Natzke RP, Newbould FHS, Nonnecke B, Thompson P.  
1979.Coliform mastitis review. J Dairy Sci. 62:1-22. 
 
61. Eberhart RJ. 1984. Coliform mastitis. Vet Clin North Am Large Anim Pract. 6: 
287-300. 
 
62. Eckmann L, Stenson WF, Savidge TC, Lowe DC, Barrett KE, Fierer J, Smith JR,  
Kagnoff MF. 1997. Role of intestinal epithelial cells in the host secretory 
response to infection by invasive bacteria: bacterial entry induces 
epithelial prostaglandin H synthase-2 expression and prostaglandin E2 and 
F2 production. J Clin Invest. 100:296-309. 
 
63. Erskine RJ, Tyler JW, Riddell MG, Wilson RC. 1991. Theory, use and realities of  
efficacy and food safety of antimicrobial treatment of acute coliform 
mastitis. J Am Vet Med Assoc. 198: 980-984. 
 
64. Ethuin F, Gerard B, Benna JE, Boutten A, Gougereot-Pocidalo MA, Jacob L,  
Chollet-Martin S. 2004. Human neutrophils produce interferon gamma 
upon stimulation by interleukin-12. Lab Invest. 84:1363-1371. 
 
65. Fearns C, Krarchenko VV, Ulevitch RJ, Loskutoff DJ. 1995. Murine CD14gene  
expression in vivo: Extramyeloid synthesis and regulation by  
lipopolysaccharide. J Exp Med. 181:857-866. 
 
66. Ferrero EF, Goyert SM. 1988. Nucleotide sequence of the gene encoding the  
monocyte differentiation antigen, CD14. Nucleic Acids Res. 16:4173. 
 
67. Feghali CA, and Wright TM. 1997. Cytokines in acute and chronic inflammation.  
Front Biosci. 2:12-26. 
 
68. Fetterer RH, Barfield RC. 2003. Characterization of a developmentally regulated  
oocyst protein from Eimeria Tenella. J Parasitol. 89:553-564. 
 
69. Filipp D, Alizadeh-Khiavi, Richardson C, Palma A, Paredes N, Takeuchi O,  
Akira S, Julius M. 2001. Soluble CD14 enriched in colostrums and milk 
induces B cell growth and differentiation. Proc Natl Acad Sci USA.
98:603-608. 
 
70.  Fletcher S, Pearce M, Tewari A, Yim H, Zou J, and Abrams JS. 1990. Anti-IL-6  
122
monoclonal antibodies protect against lethal Escherichia coli infection and 
lethal tumor necrosis factor-	 challenge in mice. J Immunol. 145:4185-
4191. 
 
71. Foxman EF, Campbell JJ, Butcher EC. 1997. Multistep navigation and the  
combinational control of leukocyte chemotaxis. J Cell Biol. 139:1349-
1360. 
 
72. Freyer EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, and  
Wright SD. 1992. Soluble CD14 participates in the response of cells to 
lipopolysaccharide. J Exp Med. 176:1665-1671.  
 
73. Freshney RI. 1994. Culture of animal cells, Third Edition. Wiley-Liss, New York, 
 107. 
 
74. Frevert CW, Matute-Bello G, Skerrett SJ, Goodman RB, Kajikawa O, Sittipunt C,  
Martin TR. 2000. Effect of CD14 blockade in rabbits with Escherichia 
coli pneumonia and sepsis. J Immunol. 164:5439-5445. 
 
75. Frey EA, Miller DS, Jahr TG, Sundan A, Bazil V, Espevik T, Finlay BB, Wright  
SD. 1992. Soluble CD14 participates in the response of cells to  
lipopolysaccharide.  J Exp Med. 176:1665-1671. 
 
76. Gately MK, Wolitzky AG, Quinn PM, Chizzonite. 1992. Regulation of human  
cytolytic lymphocyte responses by interleukin-12. Cell Immunol. 143:127-
142. 
 
77. Gray GD, Knight KA, Nelson RD, Herron MJ. 1982. Chemotactic requirements of  
bovine leukocytes. Am J Vet Res. 43:757-759. 
 
78. Grimm MC, Pavli P, Van de Pol E, Doe WF. 1995. Evidence for a CD14+
population of monocytes in inflammatory bowel disease mucosa: 
implications for pathogenesis. Clin Exp Immunol. 100: 291-297. 
 
79. Grohn YT, Wilson DJ, Gonzalez RN, Hertl JA, Schulte H, Bennett G, Schukken  
YH. 2004. Effect of pathogen-specific clinical mastitis on milk yield in 
dairy cows.  J Dairy Sci. 87:3358-3374. 
 
80. Gupta D, Kirkland TN, Viriyakosol S, Dziarski R. 1996. CD14 is a cell-activating  
receptor for bacterial peptidoglycan. Biol Chem. 20:2310-2316. 
 
81. Hakogi E, Tamura H, Tanaka S, Kohata A, Shimada Y, Tabuchi K. 1989.  
Endotoxin levels in milk and plasma of mastitis-affected cows measured 
with a chromogenic limulus test. Vet Microbiol. 20:267-274. 
 
82. Hailman E, Lichenstein HS, Wurfel MM, Miller DS, Johnson DA, Kelley M,  
123
Busse LA, Zukowski MM, Wright SD. 1994. Lipopolysaccharide (LPS)-
binding protein accelerates the binding of LPS to CD14. J Exper Med.
179:269-277. 
 
83. Hailman E, Albers JJ, Wolfbauer G, Tu AY, Wright SD. 1996. Neutralization and  
transfer of lipopolysaccharide by phospholipid transfer protein. J Biol  
Chem. 271:12172-12178. 
 
84. Weber AF. 1977. The bovine mammary gland.  J Am Vet Med Assoc. 15:1133-1136. 
 
85. Harris ES, McIntyre TM, Prescott SM, Zimmerman GA. 2000. The leukocyte  
integrins. J Biol Chem. 275:13409-13412. 
 
86. Hattar K, Fink L, Fietzner K, Himmel B, Grimminger F, Seeger W, Sibelius U. 
 2001. Cell density regulates neutrophil IL-8 synthesis: role of IL-1 
receptor antagonist and soluble TNF receptors. J Immunol. 15:6287-6293. 
 
87. Haziot  A, Cehn S, Ferrero E, Low  M, Silber R, Goyert S. 1988. The monocyte  
 differentiation antigen, CD14, is anchored to the cell membrane by a  
phosphatidylinositol linkage. J Immunol. 141:547-552. 
 
88. Haziot A, Tsuberi BZ, Goyert SM. 1993. Neutrophil CD14 biochemical  
propertices and role in the secretion of tumor necrosis factoer, 
recombinant soluble CD14. J Immunol. 15:5556-5565. 
 
89. Haziot A, Rong GW, Lin XY, Silver J, Goyert SM. 1995. Recominant soluble CD14  
prevents mortality in mice treated with endotoxin (lipopolysaccharide). J
Immunol. 15:6529-6532. 
 
90. Haziot A, Ferrero E, Kontgen F, Hijiya N, Yamamoto S, Silver J, Stewart CL, Goyert  
SM. 1996. Resistance to endotoxin shock and reduced dissemination of 
Gram-negative bacteria in CD14-deficient mice. Immunity. 4:407-414. 
 
91. Haziot A, Lin XY, Zhang F, Goyert SM. 1998. The induction of acute phage proteins  
by lipopolysaccharide uses a novel pathway that is CD14-independent.  
J Immunol. 160:2570-2572. 
 
92. Heyneman R, Burvenich C, Vercauteren R. 1990. Interaction between the respiratory 
burst activity of neutrophil leukocytes and experimentally induced 
Escherichia coli mastitis in cows. J Dairy Sci. 73:985-994. 
 
93. Hiroyoshi I, Akira T, and Shigemasa H. 2000. Prostaglandin E2 stimulates AP-1- 
mediated CD14 expression in mouse macrophages via cyclic AMP-
dependent protein kinase A.  J Immunol. 164:5403-5408. 
 
94. Hull S. 1997. In Escherichia coli: mechanism of virulence: sussman, Ed; Cambridge  
124
University press: Cambridge. Uk. 145-167. 
 
95. Ingalls RR, Golenbock DT. 1995. CD11c/CD18, a transmembrane signaling receptor  
for lipopolysaccharide. J Exp Med. 181:1473-1479. 
 
96. Ingalls RR, Arnaout MA, Golenbock DT. 1997. Outside-in signaling by  
lipopolysaccharide through a tailless integrin. J Immunol. 1:433-438. 
 
97. Ingalls RR. 1997. Lipopolysaccharide recognition, CD14 and lipopolysaccharide  
receptors bacterial sepsis and septic shock through a tailless integrin. J
Immunol. 159:433-438. 
 
98. Jain NC, Schalm OW, and Lasmanis J. 1969. Comparison in normal and  
leukopenic cows of experimental mastitis due to Aerobacter aerogenes or 
Escherichia coli endotoxin. Am J Vet Res. 30:715-724. 
 
99. Jain NC. 1986. Schalm’s Veterinary Hematology, Lea & Febiger, Philadelphia, PA,  
USA. 
 
100. Jayaram Y, Hogg N. 1989. Expression of CD14 molecules by human neutrophils.  
Tissue Antigens. 33:199-204. 
 
101. Jutila MA, Rott L, Berg EL, Butcher EC. 1989. Function and regulation of the  
neutrophil MEL-14 antigen in vivo: comparison with LFA-1 and MAC-1. 
J Immunol. 143:3318-3324. 
 
102. Kasama T, Strieter RM, Lukacs NW, Burdick MD, Kunkel SL. 1994. Regulation  
of neutrophil-derived chemokine expression by IL-10. J Immunol. 152: 
3559-3569. 
 
103. Katholm J, Andersen PH. 1992. Acute coliform mastitis in dairy cows: Endotoxin  
and biochemical changes in plasma and colony-forming units in milk. Vet 
Rec. 13:513-514. 
 
104. Kiniwa M, Gately M, Gubler U, Chizzonite R, Fargeas C, Delespesse G. 1992.  
Recombinant interleukin-12 suppresses the synthesis of immunoglobulin 
E by interleukin-4 stimulated human lymphocytes. J Clin Invest. 90:262-
266. 
 
105. Kirshning CJ, Wesche H, Ayres TM, Rothe M. 1998. Human Toll-like receptor 2  
confers responsiveness to bacterial lipopolysaccharide. J Exp Med. 188: 
2091-2097.  
 
106. Kishimoto TK, Jutila MA, Berg EL,Butcer EC. 1989. Neutrophil MAC-1 and  
MEL-14 adhesion proteins inversely regulated by chemotactic factors. 
Science. 245:1238-1241. 
125
 
107. Klein CL, Bittinger F, Kohler H, Wagner M, Otto M, Hermanns I, Kirkpatrick CJ.  
1995. Comparative studies on vascular endothelium in vitro.
Pathobiology. 63:204-212.  
 
108. Klein CL, Bittinger F, Skarke CC, Wagner M, Kohler H, Walgenbach S, Kirkpatrick 
CJ. 1995. Effects of cytokines on the expression of cell adhesion 
 molecules by cultured human mesothelial cells. Pathobiology. 64:204-
212. 
 
109. Kurt-Jones EA, Mandell L, Whitney C, Padgett A, Gosselin K, Newburger PE,  
Finberg RW. 2002. Role of Toll-like receptor 2 (TLR2) expression in   
neutrophil activation:GM-CSF enhances TLR2 expression and TLR-2 
mediated interleukin-8 responses in neutrophils. Blood. 100:1860-1868. 
 
110. Labéta MO, Durieux JJ, Fernandes N, Herrmannn R, Ferrara P. 1993. Release from  
a human monocyte-like cell line of two different soluble forms of the 
lipopolysaccharide receptor, CD14. Eur J Immunol. 23:2144-2151. 
 
111. Labéta MO, Vidal K, Nores JER, Arias M,Vita N,Morgan BP,Guillemot JC, Loyaux  
D, Ferrara P, Schmid D, Affolter M, Borysiewicz LK. 2000. Innate 
recognition of bacteria in human milk is mediated by a milk-derived 
highly expressed pattern recognition receptor, soluble CD14. J Exp Med.
15:1807-1812. 
112. Landmann R, Ludwig C, Obrist R, Obrecht JP. 1991. Effect of cytokines and  
lipopolysaccharide on CD14 antigen expression in human monocytes and 
macrophages. J Cell Biochem. 47:317-329. 
113. Landmann R, Muller B, Zimmerli W. 2000. CD14, new aspects of ligand and signal  
diversity. Microbes Infect. 2:295-304. 
 
114. Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K.1989. Production of  
IL-8 by human dermal fibroblasts and keratinocytes in response to IL-1 or 
tumor necrosis factor. Immunology. 68:31-36. 
 
115. Lau D, Mollnau H, Eiserich JP, Freeman BA, Daiber A, Gehling UM, Brummer J,  
Rudolph V, Munzel T, Heitzer T, Meinertz T, Baldus S. 2005. 
 Myeloperoxidase mediates neutrophil activation by association with 
CD11b/CD18 intergrins. Proc Natl Acad Sci USA. 11:431-436. 
 
116. Lee A, Whyte MK, Haslett C. 1993. Inhibition of apoptosis and prolongation of  
neutrophil function longevity by inflammatory mediators. J Leukocyte 
Biol. 54:283-288. 
 
117. Lee JW, Paape MJ, Elsasser TH, Zhao X. 2003. Elevated milk soluble CD14 in  
126
bovine mammary gland challenged with Escherichia coli  
lipopolysaccharide. J Dairy Sci. 86:2282-2289. 
 
118. Lee JW, Paape MJ, Zhao X. 2003. Recombinant bovine soluble CD14 reduces  
 severity of experimental Escherichia coli mastitis in mice. Vet Res.
34:307-316. 
 
119. Lee JW, Paape MJ, Elsasser TH, Zhao X. 2003. Recombinant soluble CD14  
reduces severity of intramammary infection by Escherichia coli. Infect 
Immun. 71:4034-4039. 
 
120. Lee JW, Zhao X. 2000. Recombinantion human interleukin-8, but not human  
interleukin-1 beta induces bovine neutrophil migration in an invitro-
coculture system. Cell Biol Int. 24:889-895. 
 
121. Lee KH, Lawley TJ. Xu YL, Swerlick RA. 1992. VCAM-1-, ELAM-1-, and ICAM- 
1-independent adhesion of melanoma cells to cultured human dermal 
microvascular endothelial cells. Invest Dermatol. 98:79-85. 
 
122. Leturcq DJ, Moriarty AM, Talbott RK. 1996. Antibodies against CD14 protect  
primates from endotoxin induced shock. J Clin Invest. 98:1533-1541. 
 
123. Leung TF, Tang NL, Wong GW, Fok TF. 2005. CD14 and Toll-like receptors:  
potential contribution of genetic factors and mechanisms to inflammatory 
and allergy. Curr Drug Targets Inflamm Allergy. 4:169-175. 
 
124. Loppnow H, Stelter F, Schonbeck U, Schulter C, Ernst M, Schutt C, Fald HD.   
1995. Endotoxin activates human vascular smooth muscle cells despite 
lack of expression C14 mRNA or endogenous membrane CD14. Infect 
Immun. 63:1020-1026.   
 
125. Lutcke HA, Chow KC, Mickel FS, Moss KA, Kern HF. 1987. Scheele GA.  
Selection of AUG initiation codons differs in plants and animals. EMBO J.
6:43-48. 
 
126. Lynam EB, Simon SI, Rochon YP, Sklar LA. 1994. Lipopolysaccharide enhances  
CD11b/CD18 function but inhibits neutrophil aggregation. Blood.
83:3303. 
 
127. Lynam EE, Simon SI, Rochon YP, Sklar LA. 1994. Lipopolysaccharide  
enhances CD11b/CD18 function but inhibits neutrophil aggregation. 
Blood. 83:3303-3311. 
 
128. Lynn WA, Liu Y, Golenbock DT. 1993. Neither CD14 nor serum is absolutely  
necessary for activation of mononuclear phagocytes by bacterial 
lipopolysaccharide. Infect Immun. 61:4452-4461. 
127
 
129. Maliszewski CR. 1991. CD14 and immune response to lipopolysaccharide. Science.
252:1231-1322. 
 
130. Maliszewski CR, Ball E, Graziano R, Fanger M. 1985. Isolation and characterization  
of My 23, a myeloid cell-derived antigen reactive with the monoclonal 
antibody AML-2-23. J Immunol. 135:1926-1936. 
 
131. Ma JK. 2000. Genes, greens, and vaccines. Nat Biotechnol. 18:1141-1142. 
 
132. Ma JK, Drake PM, Christou P. 2003. The production of recombinant pharmaceutical  
 proteins in plants. Nat Rev Genet. 4:794-805. 
 
133. Mason HS, Ball JM, Shi JJ, Jiang X, Estes MK. Arntzen CJ. 1996.  Expression of  
Norwalk virus caspid protein in transgenic tobacco and potato and its oral 
immunogenicity in mice. Proc Natl Acad Sci USA. 93:5335-5340.
134. Martin M, Katz J, Vogel S, Michalek S. 2001. Differential induction of  
endotoxin tolerance by lipopolysaccharides derived from Porphyromonas 
gingivalis and Escherichia coli. J Immunol. 167:5278-5285. 
135. Martin T, Rubenfeld G, Ruzinski J, Goodman R, Steinberg K, Leturcq D,  
Moriarty A, Raghu G, Baughman R, and Hudson L. 1997. Relationship 
between soluble CD14, lipopolysaccharide binding protein, and the 
alveolar inflammatory response in patients with acute respiratory distress 
syndrome. Am J Respir Crit Care Med. 155:937-944. 
 
136. Mattila T, Frost A. 1989. Induction by endotoxin of the inflammatory  
response in the lactating and dry bovine mammary gland. Res Vet Sci.
46:238-240. 
 
137. Meda L, Gasperini S, Ceska M, and Cassatella MA. 1994. Modulation of  
pro-inflammatory cytokines release from human polymorphonuclear 
leukocytes by 	 interferon. Cell Immunol. 157:448-461. 
 
138. Medzhitow R, Preston-Hurlburt P, Janeway C. 1997. A human homologue of the  
Drosophila Toll protein signals activation of adaptive immunity. Nature.
24:394-397. 
 
139. Medvedev A, Kopydlowski K, Vogel S. 2000. Inhibition of   lipopolysaccharide- 
induced signal transduction in endotoxin-tolerized mouse macrophages: 
dysregulation of cytokine, chemokine, and toll-like receptor 2 and 4 gene 
expression. J Immunol. 1:5564-5574. 
 
140. Mehrzad J, Dosogne H, Meyer E, Burvenich C. 2001. Local and systemic effects of  
128
endotoxin mastitis on the chemiluminescence of milk and blood 
neutrophils in dairy cows. Vet Res. 32:131-144. 
141. Miller RH, Paape MJ, Acton JC. 1986. Comparison of milk somatic cell counts by  
Coulter and Fossomatic Counters. J Dairy Sci. 69:1942-1946. 
 
142. Miller RH, Paape MJ, Fulton LA. 1993. The relationship of milk somatic cell count  
to milk yield for Hostein heifers after first calving. J Dairy Sci. 76:728-
733. 
 
143. Mollinedo F, Borregaard N, Boxer LA. 1999. Novel trends in neutrophil  
structure, function and development. Immunol Today. 20:535-537. 
144. Muroi M, Ohnishi T, Tanamoto K. 2002. Regions of the mouse CD14 molecule  
required for toll-like receptor 2-and 4-mediated activation of NF-kappa B. 
J Biol Chem. 277:42372-42379. 
 
145. National Mastitis Council. 1996. Current Concepts of Bovine Mastitis, 4th Edition. 
 National Mastitis Council, Madison, WI. 
 
146. Nemoto E, Sugawara S, Tada H, Takada H, Shimauchi H, Horiuchi H. 2000.  
Cleavage of CD14 on human gingival fibroblasts cocultured with 
activated neutrophils is mediated by human leukocyte lipopolysaccharide-
induced IL-8 production. J Immunol. 15:5807-5813. 
 
147. Nickerson SC, Baker PA, Trinidad P. 1989. Local immunostimulation of the bovine  
mammary gland with interleukin-2. J Dairy Sci. 72:1764-1773. 
 
148. Nourshargh S, Perkins J, Showell H, Matsushima M, Williams T, Collins P. 1992. 
A comparative study of the neutrophil stimulatory activity in vitro and 
proinflammatory properties in vivo of 72 amino acid and 77 amino acid 
IL-8. J Immunol. 48:106-111. 
 
149. Ohmann HB, Campus M, McDougall L, Lawman MJP, Babiuk LA. 1990. 
 Expression of tumor necrosis factor-? receptors on bovine macrophages, 
Lymphocytes and polymorphonuclear leukocytes, internalization of 
receptor-bound ligand, and some functional effects. Lymphokine Res.
9:43-58. 
 
150. Östensson K, Hageltorn M, Aström G. 1998. Differential cell counting in fractions 
collected milk from dairy cows. Acta Veterinaria Scandinavica. 29:493-
500. 
 
151. Paape MJ, Lilius EM, Wiitanen PA, Konitio MP, Miller RH. 1996. Intrammamary  
 defense against infections induced by Escherichia coli in cows. Am J 
 Vet Res. 4:477-482. 
129
 
152. Burvenich C, Paape MJ, Hill, Guidry AW, Miller RH, Heyneman R, Kremer WD,  
Brand A. 1994. Role of the neutrophil leukocyte in the local and systemic 
reactions during experimentally induced E.coli mastitis in cows  
 immediately after calving. Vet Q. 16:45-50. 
 
153. Paape MJ, Lilius EM, Wiitanen PA, Kontio MP, Miller RH. 1996. Intramammary  
 defense against infections induced by Escherichia coli in cows. Am J Vet        
 Res. 57:477-482. 
 
154. Paape MJ, Rautiainen PM, Lilius EM, Malstrom CE, Elsasser TH. 2002. 
Development of anti-bovine TNF-alpha mAb and ELISA for quantitating 
TNF-? in milk after intramammary injection of endotoxin. J Dairy Sci.
85:765-773. 
 
155. Paape MJ, Bannerman DD, Zhao X, Lee JW. 2003. The bovine neutrophil: Structure  
and function in blood and milk. Vet Res. 34:597-627. 
 
156. Paape MJ, Schultze WD, Desjardins C, Miller RH. 1974. Plasma corticosteroid,  
circulating leukocyte and milk somatic cell responses to Escherichia coli 
endotoxin-induced mastitis. Proc Soc Exp Biol Med. 145:553-559. 
 
157. Parsons PE, Gillespie MM, Moore EE, Moore FA, Worthen GS. 1995.  
Neutrophil response to endotoxin in the adult respiratory distress 
syndrome: role of CD14. Am J Respir Cell Mol Biol. 1:152-160. 
 
158. Payne CM, Glasser L, Tischler ME, Wyckoff D, Cromey D, Fiederlein R, Bohnert  
O. 1994. Programmed cell death of the normal human neutrophil: An in 
vitro model of senescence. Microsc Res Tech. 28:327-344. 
 
159. Perera PY, Vogel SN, Detore GR, Haziot A, Goyert SM. 1997. CD14-depedent and  
CD14-independent signaling pathways in murine macrophages from 
normal and CD14 knockout mice stimulated with lipopolysaccharide or 
taxol. J Immunol. 158:4422-4429. 
 
160. Peveri P, Walz A, Dewald B, Baggiolini M. 1988. A novel neutrophil activating  
factor produced by human mononuclear phagocytes. J Exp Med.
167:1547-1559. 
161. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, Birdwell D, Alejos E,  
Silva M, Galanos C, Freudenberg M, Ricciardi-Castagnoli P, Layton B, 
Beutler B. 1998. Defective LPS signaling in C3H/He J and C57BL/10Sc 
Cr mice: mutations in Tlr-4 gene. Science. 282:2085-2088. 
 
162. Pugin J, Heumann ID, Tomasz A, Kravchenko VV, Akamatsu Y, Nishijima M,  
130
Glauser MP, Tobias PS, Ulevitch RJ. 1994. CD14 is a pattern recognition 
receptor. Immunity. 1:509-516. 
163. Pugin J, Ulevitch RJ, Tobias PS. 1995. Activation of endothelial cells by endotoxin:  
direct versus indirect pathways and the role of CD14. Prog Clin Biol Res.
392:369-373. 
 
164. Pujin J, Heumann D, Tomzas A, Kravchenko VV, Akamatsu Y, Nishijima M,  
Glauser MP, Tobias PS, Ulevitch RJ. 1994. CD14 is a pattern recognition 
receptor. Immunity. 1:509-516.  
 
165. Rabinowich H, Herbeman RB, Whiteside TL. 1993. Differential effects of IL-12 and  
IL-2 on expression and function of cellular adhesion molecules on purified 
human NK cells. Cell Immunol. 152:481-498. 
 
166. Raetz CR. 1993. Bacterial endotoxins: extraordinary lipids that activate eucaryotic  
signal transduction. J Bacteriol. 175:5745-5753. 
 
167. Randow F, Syrbe U, Meisel C, Krausch D, Zuckermann H, Platzer C, Volk HD. 
1995. Mechanism of endotoxin desensitization: involvement of interleukin 
10 and transforming growth factor beta. J Exp Med. 1:1887-1892.  
 
168. Reddi K, Phagoo SB, Anderson KD, Warburton D. 2003. Burkholderia cepacia- 
induced IL-8 gene expression in an alveolar epithelial cell line:signalling 
through CD14 and mitogen-activated protein kinase. Pediatric research.
54:297-305. 
 
169. Reddy PG, Blecha F, Minocha HC, Anderson GA, Morrill JL, Fedorka-Cray PJ,  
Baker PE. 1989. Bovine recombinant interleukin-2 augments immunity 
and resistance to bovine herpesvirus infection. Vet Immunol  
Immunopathol. 30:61-74. 
170. Riollet C, Rainard P, Poutrel B. 2000. Cells and cytokines in inflammatory  
secretion of bovine mammary gland. Adv Exp Med Biol. 480:247-258. 
 
171. Riollet C, Painard P, Poutrel B. 2000. Kinetics of cells and cytokines during  
immune-mediated inflammation in the mammary gland of cows  
systemically immunized with Staphylococcus aureus alpha-toxin. Inflamm 
Res. 49:486-496. 
 
172. Riollet C, Rainard P, Poutrel B. 2000. Differential induction of complement  
fragment C5a and inflammatory cytokines during intramammary 
infections with Escherichia coli and Staphylococcus aureus. Clin Diagn 
Lab Immunol. 7:161-167. 
 
173. Robson RL, McLoughlin RM, Witowski J, Loetscher P, Wilkinson TS, Jones SA,  
131
 Topley N. 2001. Differential regulaton of chemokine production in human 
 Peritoneal mesthelial cells: INF-gamma controls neutrophil migration  
across the mesothelium in vitro and in vivo. J Immunol. 167:1028-1038. 
 
174. Roderberg DA, Morris RE, Babcock GF. 1997. Azurophilic granules of human  
 neutrophils contain CD14. Infect Immun. 65:4747-4753. 
 
175. Ross GD, Vetvicka V. 1993. CR3 (CD11b, CD18):a phagocyte and NK cell  
membrane receptor with multiple ligand specificities and functions. Clin 
Exp Immunol. 92:181-184. 
 
176. Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA.  
1989. Tumor necrosis factor and interleukin 1 alpha increase vascular 
endothelial permeability. Am J Physiol. 257:L399-410. 
 
177. Savedra R Jr, Delude RL, Ingalls RR, Fenton MJ, Golenbock DT. 1996.  
Mycobacterial lipoarabinomannan recognition requires a receptor that 
shares components of the endotoxin signaling system. J Immunol.
15:2549-2554. 
 
178. Schletter J. Heine H, Ulmer AJ, Rietschel ET. 1995. Molecular mechanisms of  
endotoxin activity. Arch Microbiol. 164:383-389. 
 
179.  Schnyder-Candrian S, Strieter RM, Kunker SL, Walz A. 1995. Interferon-alpha 
 and interferon-gamma down-regulate the production of interleukin-8 and   
 ENA-78 in human monocytes. J Leukoc Biol. 57:929-935. 
 
181. Schmaljohn CS, Chu YK, Schmaljohn AL, Dalrymple JM. 1990. 
Antigenic subunits of Hantaan virus expressed by baculovirus and 
vaccinia virus recombinants. J Virol. 64:3162-3170. 
 
182. Schumann RR, Leong SR, Flaggs GW, Gray PW, Wright SD, Mathison JC, Tobias  
PS, Ulevitch RJ. 1990. Structure and function of lipopolysaccharide  
binding protein. Science. 249:1429-1431. 
 
183. Schutt C, Schilling T, Grunwald U, Schonfeld W, Kruger C. 1992. Endotoxin  
neutralizing capacity of soluble CD14. Res Immunol. 143:71-78. 
 
184. Schimke J, Mathison J, Morgiewicz J, Ulevitch R. 1998. Anti-CD14 mAb treatment  
provides therapeutic benefit after in vivo exposure to endotoxin. Proc Natl 
Acad Sci USA. 95:13875-13380. 
 
185. Seiler P, Aichele P, Raupach B, Odermatt B, Steinhoff U, Kaufmann HE. 2000.  
Rapid neutrophil response controls fast-replicating intracellular bacteria 
 but not slow-replicating mycobacterium tuberculosis. J Infect Dis. 181:67-  
80. 
132
 
186. Sengelov IL, Kjeldsen L, Dianmond MS, Springer TA, Borregaard N. 1993.  
Subcellular localization and dynamics of Mac-1 (?m B2) in human 
neutrophils. J Clin Invest. 92:1467-1476. 
 
187. Shapiro RA, Cunningham MD, Ratcliffe K, Seachord C, Blake J, Bajorath A, Aruffo  
A, Dadveau P. 1997. Identification of CD14 residues involved in specific 
lipopolysaccharide recognition.  Infect Immun. 243:100-109. 
 
188. Shilo M. 1959. Non-specific resistance to infection. Ann Rev Microbial. 13:255-270.  
 
189. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, Kimoto M. 1999.  
MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-
like receptor 4. J Exp Med. 189:1777-1782. 
 
190. Shimizu T, Yokota SI, Takahashi S, Kunishima Y, Takeyama K, Masumori  N, 
Takahashi A, Naoki M, Taiji Tsukamoto T, Fujii N. 2004. Membrane-
anchored CD14 is important for induction of interleukin-8 by 
lipopolysaccharide and peptidoglycan in uroepithelial cells. Clinical and 
Diagnostic Laboratory Immunology. 11:969. 
 
191. Shuster DE, Kehrli ME, Rainard P, Paape MJ. 1997. Complement fragment C5a and  
inflammatory cytokines in neutrophil recruitment during intramammary 
infections with Escherichia coli. Infect Immun. 65:3286-3292. 
 
192. Shuster DE, Lee EK, Kehrli ME. 1996. Bacterial growth, inflammatory cytokine  
production, and neturophil recruitment during coliform mastitis in cows 
within ten days after calving compared with cows at midlactation. Am J 
Vet Res. 57:1569-1575. 
 
193. Shuster DE, Kehrli ME, Stevens MG. 1993. Cytokine production during endotoxin – 
induced mastitis in lactating dairy cows. Am J Vet Res. 54:80-85. 
 
194. Smits E, Burvenich C, Guidry AJ, Heyneman R, Massart-Leen AM. 2000. Adhesion  
receptor CD11b/CD18 contributes to neturophil diapedesis across the 
bovine blood-milk barrier. Vet Immunol. 73:255-265. 
 
195. Smith KL, Hogan JS. 1993. Environmental mastitis. W.B. Saunders Company. 
489-498. 
 
196. Smits E, Burvenich C, Guidry AJ, Heyneman R, Massart-Leen A. 1999. Diapedesis  
across mammary epithelium reduces phagocytic and oxidative burst of 
bovine neutrophils. Vet Immunol Immunopathol. 68:169-176. 
 
197. Smits E, Burvenich C, Guidry AJ, Massart-Leen A. 2000. Adhesion receptor  
133
CD11b/CD18 contributes to neutrophil diapedesis across the bovine 
blood-milk barrier. Vet Immunol Immunopathol. 15:255-265. 
 
198. Sohn EJ, Paape MJ, Peters RR, Fetterer RH, Talbot NC, Bannerman DD. 2004. 
 The production and characterization of anti-bovine CD14 monoclonal 
 antibodies. Vet Res. 35:597-608. 
 
199. Sordillo LM, Streicher KL. 2002. Mammary gland immunity and mastitis  
susceptibility. J Mammary Gland Biol Neoplasia. 7:135-146. 
 
200. Sordillo LM, Babiuk LA. 1991. Modulation of bovine mammary neutrophil function  
during the periparturient period following in vitro exposure to 
recombinant bovine interferon gamma. Vet Immunol Immunopathol.
27:393-402. 
 
201. Springer TA. 1994. Traffic signals for lymphocyte recirculation and leukocyte  
emigration:The multistep paradigm. Cell. 76:301-314. 
 
202. Stelter F, Bernheiden M, Menzel R, Jack RS, Witt S, Fan X, Phister M, Schutt C. 
 1997. Muation of amino acid 39-44 of human CD14 abrogates bindng of  
 lipopolysaccharide and Escherichia coli. Eur J Biochem. 243:100-109. 
 
203. Steinbeck MJ, Roth JA. 1989. Neutrophil activation by recombinant cytokines. Rev  
Infect Dis. 11:549-568. 
 
204. Stelter F, Pfister M, Bernheiden M, Jack RS, Bufler P, Engelmann H, Schutt C.  
1996. The myeloid differentiation antigen CD14 in N- and O-
glycosylated:contribution of N-linked glycosylation to different soluble 
CD14 isoforms. Eur J Biochem. 236:457-464. 
 
205. Stelter F, Witt S, Furll B, Jack RS, Hartung T, Schutt C. 1998. Different efficacy of  
soluble CD14 treatment in high and low dose LPS. J Immunol. 15:5556-
5565. 
 
206. Struyf S, Van Collie E, Paemen L, Put W, Lenaerts JP, Proost P, Opdenakker G,  
Van Damme J. 1998. Synergistic induction of MCP-1 and-2 by IL-1B and 
interferons in fibroblasts and epithelial cells. J Leukoc Biol. 63:364-372.  
 
207. Streatfield  S J, Howard JA. 2003. Plant-based vaccines. Int J Parasitol. 33:479- 
493. 
 
208. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K, Akira  
S. 1999. Differential roles of TLR2 and TLR4 in recognition of Gram-
negative and Gram-positive bacterial cell wall components. Immunity.
11:443-451.  
 
134
209. Taub DD, Lloyd AR, Wang JM, Oppenheim JJ, Kelvin DJ. 1993. The effects of  
human recombinant MIP-1 alpha, MIP-1 beta, and RANTES on the 
chemotaxis and adhesion of T cell subsets. Adv Exp Med Biol. 351:139-
146. 
 
210. Tobias PS, Soldau K, Ulevitch RJ. 1986. Isolation of a lipopolysaccharide-binding  
acute phase reactant from rabbit serum. J Exp Med. 71:285-293. 
 
211. Tobias PS, Soldau K, Gegner JA, Mintz D, Ulevitch RJ. 1995. Lipopolysaccharide      
 binding protein-mediated complexation of lipopolysacchardie with      
 soluble CD14. J Biol Chem. 270:10482-10488. 
 
212. Trine L, Bjarneh. 2004. The effect of TNF-, PMA, and LPS on plasma and cell  
 associated IL-8 in human leukocytes. Thrombosis Research. 113:75-83. 
 
213. Trincheri G. 1995. Interleukin-12: a proinflammatory cytokine with  
immunoregulatory functions that bridge innate resistance and antigen-
specific adaptive immunity. Annu Rev Immunol. 13:251-276. 
 
214. Triantafilow M, Trinatafilou K, Fernandez N. 2000. Rough and smooth forms of  
 fluorescein-labelled bacteria endotoxin exhibit CD14/LBP dependent and  
 independent binding that is influenced by endotoxin concentration. Eur J 
 Biochem. 8:2218-2226. 
 
215. Triantafilou M, Triantafilou K. 2002. Lipopolysaccharide recognition: CD14, TLRs  
and the LPS-activation cluster. Trends Immunol. 23:301-304. 
 
216. Troelstra A, de Graaf-Miltenburg LA, van Bommel T, Verhoef J, Van Kessel KP,  
Van Strijp JA. 1999. Lipopolysaccharide-coated erythrocytes activate 
human neutrophils via CD14 while subsequent binding is through 
CD11b/CD18. J Immunol. 1:4220-4225. 
217. Ulevitch RJ, Tobias PS. 1999. Recognition of Gram-negative bacteria and endotoxin  
by the innate immune system. Curr Opin Immunol. 11:19-22. 
 
218. Waage S, Mork T, Roros A, Aasland D, Hunshamar A, Odegaard SA. 1999.  
Bacteria associated with clinical mastitis in dairy heifers. J Dairy Sci.
82:712-719. 
 
219. Wang Y, Zarlenga DS, Paape MJ, Dahl GE. 2002. Recombinant bovine soluble  
 CD14 sensitizes the mammary gland to lipopolysaccharide. Vet Immunol      
 Immunopathol. 86:115-124. 
 
220. Wang Y, Paape MJ, Leino L, Capuco AV, Narva H. 1997. Functional and  
phenotypic characterization of monoclonal antibodies to bovine L-selectin. 
Am J Vet Res. 58:1392-1401. 
135
 
221. Watson RWG, Redmond HP, Wang JH, Bouchier-Hayes D. 1996. Bacterial  
ingestion, tumor necrosis factor-alpha, and heat induce programmed cell 
death in activated neutrophils. Shock. 5:47-51. 
 
222. Watson RW, Redmond HP, Wang JH, Condron C, Bouchier-Hayes D. 1996.  
Neutrophils undergo apoptosis following ingestion of Escherichia coli. J
Immunol. 15:3986-3992. 
 
223. Weiss SJ. 1989. Mechanisms of disease: tissue destruction by neutrophils.  
 N Engl J Med. 320:365-376. 
 
224. Wertheim WA, Kunkel SL, Standford TJ, Burdick MD, Becker FS, Wilke CA,  
Gilbert AR, Strieter RM. 1993. Regulation of neutrophil-derived IL-8:the 
role of prostaglandin E2, dexamethasone, and IL-4. J Immunol. 151:2166-
2175. 
 
225. Wilson RW, Ballantyne CM, Smith CW, Montgomery C, Bardley A, O’Brien WE,  
 Beaudet AL. 1993. Gene targeting yields a CD18-mutant mouse for study 
of inflammation. J Immunol. 151:1571-1578. 
 
226. Wright SD Toll. 1999. A new piece in the puzzle of innate immunity. J Exp Med.
5:605-609. 
 
227. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. 1990. CD14, a                                
receptor for complexes of lipopolysaccharide (LPS) and LPS binding  
protein. Science. 249:1431-1433. 
 
228. Wurfel MM, Hailman E, Wright SD. 1995. Soluble CD14 acts as a shuttle in the  
neutralization of lipopolysaccharide (LPS) by LPS-binding protein and 
reconstituted high density lipoprotein. Exp Med. 1:1743-1754. 
229. Yang RB, Mark MR, Huang A, Xie MH, Zang M, Goddard A, Wood WI, Gurney  
AL, Godowski PJ. 1998. Toll-like receptor-2 mediates lipopolysaccharide-
induced cellular signaling. Nature. 395:284-288. 
 
230. Yethon JA, Whitfield C. 2001. Lipopolysaccharide as a target for the development  
of novel therapeutics in gram-negative bacteria. Curr Drug Targets Infect 
Disord. 2:91-106. 
 
231. Yoshimatsu K, Arikawa J, Kariwa H. 1993. Application of a recombinant  
baculovirus expressing hantavirus nucleocapsid protein as a diagnostic 
antigen in IFA test: cross reactivities among 3 serotypes of hantavirus 
which causes hemorrhagic fever with renal syndrome (HFRS). J Vet Med 
Sci. 55:1047-1050. 
 
136
232. Yusibov V, Modelska A, Steplewski K, Agadjanyan M, Weiner D, Hooper DC,  
Koprowski H. 1997. Antigens produced in plants by infection with 
chimeric plant viruses immunize against rabies virus and HIV-1. Proc 
Natl Acad Sci U S A. 27:5784-5788. 
 
233. Zhou X, Gao XP, Fan J, Liu Q, Anwar KN, Frey RS, Malik AB. 2004. LPS 
activation of toll-like receptor (TLR4) signals CD11b/CD18 expression in 
neutrophils. Am J Physiol Lung Cell Mol Physiol. 288:655-662. 
 
234. Van Amersfoort ES, Van Berkel TJ, Kuiper J. 2003. Receptors, mediators and  
mechanisms involved in bacterial sepsis shock. Clin Microbiol Rev.
16:379-414. 
 
235. Van Furth AM, Verhard-Seijmonsbergen EM, Langermans JAM, Van Dissel JT,  
Van Furth R. 1999. Anti-CD14 monoclonal antibodies inhibit the 
production of tumor necrosis factor alpha and interleukin-10 by human 
monocytes stimulated with killed and live Haemophilus influenzae or 
Streptococcus pneumoniae organisms. Infect Immun. 67:3714-3718. 
 
236. Van Oostveldt K, Paape MJ, Dosogne H, Burvenich C. 2002. Effect of apoptosis on  
phagocytosis, respiratory burst and CD18 adhesion receptor expression of 
bovine neutrophils.  Domest Anim Endocrinol. 22:37-50. 
 
237. Vandeputte-Van Messom G, Burvenich C, Roets E, Massart-Leën A,  
Heyneman R, Kremer WDK, and Brand A. 1993. Classification of newly 
calved cows into moderate and severe responders to experimentally 
induced Escherichia coli mastitis. J Dairy Res. 60:19-29. 
 
238. Van Oostveldt K, Tomita GM, Paape MJ, Capuco AV, Burvenichh C. 2002. 
 Apoptosis of bovine neutrophils during mastitis experimentally induced   
 with Escherichia coli or endotoxin. Am J Vet Res. 63:448-453. 
 
239. Verbon A, Dekkers PE, Van Hove T, Hack CE, Pribble JP, Turner T, Souza S, 
Axtelle T, Hoek FJ, Van Deventer SJ, Van der Poll T. 2001. IC, anti-
CD14 antibody, inhibits endotoxin-mediated symptoms and inflammatory 
responses in humans. J Immunol. 166:3599-3605. 
 
240. Viriyakosol S, Kirkland TN. 1996. The N-terminal half of membrane CD14 is a   
functional cellular lipopolysaccharide receptor. Infect Immunity. 64:653-
656.                       
 
251. Glauser MP, Heumann D, Baumgartner JD, Cohen J. 1994. Pathogenesis and  
 potential strategies for prevention and treatment of septic shock: an update.  
 Clin Infect Dis. 2:S205-216. 
 
136
